Methods and compositions for treating lipoprotein-associated diseases

CN119053705APending Publication Date: 2024-11-29CRISPR THERAPEUTICS AG
0 Cites 1 Cited by

Patent Information

Application Number
CN202380037582.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-28
Filing Date
2023-03-20
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Currently, there are no effective drugs that directly target lipoprotein(a). High levels of Lp(a) are associated with an increased risk of cardiovascular disease. Existing drugs, such as statins, cannot regulate Lp(a) levels, leading to a high incidence and rapid progression of cardiovascular disease.

Method used

Using the RNA-guided DNA targeting technology of the CRISPR-Cas system, gene editing was performed to reduce Lp(a) levels by administering guide RNA targeting the LPA gene and nanoparticles encoding RNA-guided endonuclease to the subjects.

Benefits of technology

It significantly reduces Lp(a) levels in the plasma of subjects, achieving a reduction effect of 20% to over 90%, lasting for weeks to years, and effectively treating lipoprotein-related diseases such as calcifying aortic valve disease and myocardial infarction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053705A_ABST
    Figure CN119053705A_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods, compositions and kits for modulating the expression of an LPA gene in a subject by gene editing and for treating lipoprotein-associated diseases, such as cardiovascular diseases.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Patent Application No. 63 / 322,078, filed on March 21, 2022, U.S. Provisional Patent Application No. 63 / 351,542, filed on June 13, 2022, and U.S. Provisional Patent Application No. 63 / 385,093, filed on November 28, 2022. The contents of these related applications are incorporated herein by reference in their entireties for all purposes. Reference to a sequence listing

[0002] This application is submitted with a sequence listing in electronic format. The sequence listing is provided as a file entitled 80EM-341712-WO_SeqList, which was created on March 15, 2023 and is 35.9 kilobytes in size. The information in the electronic sequence listing is incorporated herein by reference in its entirety. background

[0003] field The present disclosure relates generally to the fields of molecular biology and biotechnology, including gene editing. Description of the Prior Art

[0004] Lipoprotein (a) (Lp(a)) is an atherogenic lipoprotein composed of the protein apolipoprotein (a) [apo(a)] covalently bound to the apolipoprotein B-100 (apoB) component of low-density lipoprotein (LDL) particles. High levels of Lp(a) are associated with an increased risk of cardiovascular disease, including, for example, calcific aortic valve disease (high levels of Lp(a) lead to a higher incidence and more rapid progression of the disease), myocardial infarction (MI), coronary heart disease, atherosclerosis, thrombosis, and stroke. There are currently no approved drugs that directly target Lp(a).

[0005] Targeting DNA using the RNA-guided DNA targeting principle of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR-associated) systems has been widely used. CRISPR-Cas systems can be divided into two categories, where Class 1 systems utilize a complex of multiple Cas proteins (such as Type I, Type III, and Type IV CRISPR-Cas systems), and Class 2 systems utilize a single Cas protein (such as Type II, Type V, and Type VI CRISPR-Cas systems). Type II CRISPR-Cas-based systems have been used for genome editing, and require Cas polypeptides or variants thereof guided by customizable guide RNAs (gRNAs) for programmable DNA targeting.

[0006] There is a need for safe and effective gene editing strategies to treat lipoprotein-related diseases such as cardiovascular disease and calcific aortic valve disease by reducing Lp(a) levels. Overview

[0007] The content disclosed herein includes methods, compositions and kits for treating lipoprotein-related diseases. Some embodiments provide a method for treating lipoprotein-related diseases in a subject in need thereof, the method comprising administering to the subject more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting the LPA gene (LPA gRNA) or a nucleic acid encoding the LPA gRNA; and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby treating the subject's lipoprotein-related diseases. More than one nanoparticle may be administered to the subject twice or more. In some embodiments, each of the two or more administrations is spaced from about two weeks to about four weeks. In some embodiments, each of the two or more administrations is spaced from at least three months. In some embodiments, the method comprises administering more than one nanoparticle to the subject at a single time.

[0008] In some embodiments, LPA expression in the subject's plasma is reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% after administration. In some embodiments, the concentration of LPA protein in the subject's plasma is reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% after administration. In some embodiments, the reduction lasts for three weeks, four weeks, five weeks, two months, three months, six months, one year, two years, three years, five years, ten years, fifteen years, or more after administration. In some embodiments, the reduction is 65% one month after administration. In some embodiments, the reduction is 75% three months after administration. In some embodiments, the reduction is relative to (a) LPA expression or concentration of LPA protein in the plasma of a subject before administration of more than one nanoparticle; (b) LPA expression or concentration of LPA protein in one or more untreated subjects; and / or (c) a reference level of LPA expression or concentration of LPA protein in healthy subjects.

[0009] A subject in need may have an Lp(a) level of greater than 50 mg / dl, e.g., 60 mg / dl, 70 mg / dl, 80 mg / dl, 90 mg / dl, 100 mg / dl, 110 mg / dl, 120 mg / dl, 130 mg / dl, 140 mg / dl, 150 mg / dl, 200 mg / dl, 250 mg / dl, 300 mg / dl or more. In some embodiments, a subject in need has an Lp(a) level greater than 100 mg / dL. In some embodiments, a subject in need has an increased risk of myocardial infarction (MI) unrelated to established cardiovascular disease (CVD) risk factors, or an increased lifetime risk of atherosclerotic cardiovascular disease (ASCVD).

[0010] The methods described herein may include measuring the blood or serum level of Lp(a) in the subject before, during, and / or after administration. In some embodiments, the method includes identifying a subject in need of treatment.

[0011] Lipoprotein related diseases can be metabolic diseases, cardiovascular diseases, lipid metabolism diseases or their combinations. In some embodiments, lipoprotein related diseases are calcific aortic valve disease, myocardial infarction, coronary heart disease, atherosclerosis, thrombosis, stroke, coronary artery disease, familial hyperlipidemia, myocardial infarction, peripheral artery disease, calcific aortic valve stenosis or their combinations. In some embodiments, one or more symptoms of the lipoprotein related diseases of the subject are alleviated or relieved. In some embodiments, more than one nanoparticle of the composite is administered to the subject to reduce cardiovascular risk, the probability of death associated with cardiovascular events or their combinations.

[0012] In some embodiments, the nucleic acid encoding the RNA-guided endonuclease is an mRNA of an RNA-guided endonuclease (e.g., Cas9 endonuclease). Non-limiting examples of Cas9 endonucleases include Streptococcus pyogenes (S. Pyogenes) Cas9, Staphylococcus aureus (S. aureus) Cas9, Neisseria meningitidis (N. meningitides) Cas9, Streptococcus thermophilus (S. thermophilus) Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola (T.denticola) Cas9 and variants thereof. gRNA can be a single guide RNA (sgRNA). In some embodiments, gRNA targets exon 3 of the LPA gene. In some embodiments, the LPA gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25. In some embodiments, the LPA gRNA comprises a spacer sequence of SEQ ID NO: 18. In some embodiments, the LPA gRNA is a single guide RNA (sgRNA) comprising a sequence of SEQ ID NO: 32. In some embodiments, the LPA gRNA is a single guide RNA (sgRNA) comprising the sequence of SEQ ID NO: 11.

[0013] The LPA gRNA or nucleic acid encoding the LPA gRNA and the RNA-guided nuclease can be encapsulated in more than one nanoparticle. In some embodiments, the nanoparticle is a lipid nanoparticle. The subject can be a primate subject, such as a human.

[0014] In some embodiments, the method comprises administering more than one nanoparticle to a subject in a single administration. For example, more than one nanoparticle can be administered to a subject in a single administration at or about the following doses: 0.1 mg / kg, 0.3 mg / kg, 0.6 mg / kg, or 1 mg / kg of total nucleic acid (a) and (b).

[0015] In some embodiments, more than one nanoparticle is a lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymer-conjugated lipids. In some embodiments, the lipid nanoparticle comprises cholesterol, polyethylene glycol (PEG) lipids, or both.

[0016] The method may also include determining the level of one or more of (i) alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (Alk Phos) and albumin in the subject before, after, or both; (ii) prothrombin time (PT) and / or (iii) partial thromboplastin time (PTT). In some embodiments, the subject is administered additional treatment, wherein the additional treatment includes administration of corticosteroids, anti-H1 antihistamines, anti-H2 antihistamines, or any combination thereof. Additional treatment can be administered to a subject 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week or more before administering more than one nanoparticle to the subject. In some embodiments, additional treatment and more than one nanoparticle are administered simultaneously.

[0017] The content disclosed herein includes a composition comprising more than one nanoparticles complexed with (a) a guide RNA (gRNA) targeting the LPA gene (LPAgRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25. The content disclosed herein also includes a composition for use in the treatment of lipoprotein-related diseases, comprising more than one nanoparticles complexed with (a) a guide RNA (gRNA) targeting the LPA gene (LPA gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25. Lipoprotein-related diseases can be metabolic diseases, cardiovascular diseases, lipid metabolism diseases, or a combination thereof. In some embodiments, the lipoprotein-related disease is calcific aortic valve disease, myocardial infarction, coronary heart disease, atherosclerosis, thrombosis, stroke, coronary artery disease, familial hyperlipidemia, myocardial infarction, peripheral artery disease, calcific aortic valve stenosis, or a combination thereof. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 18. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 32. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 11. The Cas9 endonuclease can be a Streptococcus pyogenes Cas9 endonuclease. In some embodiments, more than one nanoparticle is a lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymer-conjugated lipids. In some embodiments, the lipid nanoparticle comprises cholesterol, polyethylene glycol (PEG) lipids, or both. In some embodiments, the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 An exemplary lipoprotein(a) (Lp(a)) structure is depicted.

[0019] Figure 2 A non-limiting exemplary non-human primate (NHP) study design is depicted.

[0020] Figure 3A-3B Depicted is a graph showing group 4 NHP ( Figure 3A ) and group 5 NHP ( Figure 3B ) of plasma Lp(a) levels.

[0021] Figure 4A-4B Depicted is a graph showing group 4 NHP ( Figure 4A ) and group 5 NHP ( Figure 4B) of the plasma Lp(a) levels in the subjects.

[0022] Figure 5 A non-limiting exemplary experimental design is depicted. Endpoints include, but are not limited to: Hematology: d-14 (i.e., day -14), d-7 (i.e., day -7), d7 (i.e., day 7), d15, d29, d43, d57, d71 and / or d84; serum chemistry: d-14, d-7, d2, d4, d7, d10, d15, d29, d43, d57, d71 and / or d84; coagulation: d-14, d-7, d15, d29, d43, d57, d71 and / or d84; ECG: d-12, d2, d22 and / or d84; bioanalytical: d-7, d1, d2, d4, d8, d15, d29, d43, d57, d71 and / or d84; biomarkers: d-14, d-7, d8, d15, d29, d43, d57, d71 and / or d84; and edited in tissues: the tissue list includes reproductive tissues.

[0023] Figure 6 is a graph showing baseline Lp(a) levels in NHP plasma 14 days prior to treatment (Day -14).

[0024] Figure 7 A non-limiting exemplary NHP study design is depicted.

[0025] Fig. 8A is a graph showing the percent change from baseline in plasma Lp(a) protein levels of NHPs following treatment with three different doses of CTX320: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg, compared to the control group. Figure 8B is a graph showing the percent change from baseline in serum Lp(a) protein levels of NHPs following treatment with three different doses of CTX320: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg, compared to the control group.

[0026] Figure 9A-9C is a graph showing plasma Lp(a) protein levels in NHPs before and after treatment with three different doses of CTX320: 0.5 mg / kg ( Fig. 9A )、1.5 mg / kg ( Fig. 9B ) and 3.0 mg / kg ( Fig. 9C ). Fig.9D is a graph showing the percent change from baseline in plasma Lp(a) levels of NHPs on day 29 after CTX320 treatment.

[0027] Fig. 10Ais a graph showing the percent change from baseline in serum Lp(a) protein levels of NHPs following treatment with three different doses of CTX320: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg, compared to the control group. Fig. 10B Shown are the percent changes from baseline in plasma Lp(a) levels of NHPs after approximately 3 months of CTX320 treatment.

[0028] Fig.11 is a graph showing the percentage of LPA gene editing in liver and other organ tissues including spleen, adrenal glands, brain, kidney, lung, epididymis, testis, and ovary.

[0029] Figure 12A-12C is a graph showing editing of reproductive tissues after administration of CTX320.

[0030] Figure 13A-13B is a graph showing plasma levels of LNP component A after treatment.

[0031] Figure 14A-14B is a graph showing plasma levels of LNP component B after treatment.

[0032] Fig.15 A non-limiting exemplary design for a Phase 1 safety and tolerability clinical study of one or more of the LPA gene editing nanoparticles described herein (e.g., CTX320) is shown.

[0033] Fig.16 is a graph showing the percent change from baseline in serum Lp(a) protein levels of patients following CTX320 treatment. Patients were pretreated with steroids and antihistamines.

[0034] Fig.17 A graph is provided comparing aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin levels in patients pretreated with steroids and antihistamines prior to CTX320 administration (2.0 mg / kg) and in patients not pretreated and treated with 1.5 mg / kg and 3 mg / kg CTX320. Details

[0035] Reference is made to the accompanying drawings forming a part of this document in the following detailed description. In the accompanying drawings, similar symbols generally identify similar components unless the context otherwise indicates. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure as generally described herein and illustrated in the accompanying drawings can be arranged, replaced, combined, separated, and designed in a variety of different configurations, all of which are expressly contemplated herein and form a part of the present disclosure.

[0036] All patents, published patent applications, other publications, and sequences from GenBank and other databases mentioned herein are incorporated by reference in their entirety with respect to the relevant art.

[0037] High levels of Lp(a) are associated with an increased risk of cardiovascular disease. Lp(a) levels greater than 50 mg / dL (e.g., >125 nmol / L) can cause calcific aortic valve disease (CAVD) and cardiovascular disease (CVD). Unlike low-density lipoprotein, Lp(a) levels cannot be regulated by the environment, diet, exercise, or existing lipid-lowering drugs such as statins, making it a genetically driven disease risk factor. There are currently no approved drugs that directly target Lp(a). The present disclosure provides methods, compositions, systems, and kits for regulating (e.g., reducing) Lp(a) levels in subjects in need thereof to reduce the risk of cardiovascular disease and / or treat cardiovascular disease.

[0038] Disclosed herein include methods, compositions and kits for treating cardiovascular diseases or disorders in subjects (e.g., primate subjects). In some embodiments, the method includes administering to a subject in need thereof more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an LPA gene or a nucleic acid encoding a gRNA targeting an LPA gene and (b) a nucleic acid (e.g., mRNA) encoding an RNA-guided endonuclease, thereby treating the subject's cardiovascular disease or disorder.

[0039] definition As used herein, the term "about" means plus or minus 5% of the provided value.

[0040] As used herein, the term "RNA-guided endonuclease" refers to a polypeptide that can bind to RNA (e.g., gRNA) to form a complex that targets a specific DNA sequence (e.g., in a target DNA). A non-limiting example of an RNA-guided endonuclease is a Cas polypeptide (e.g., a Cas endonuclease, such as a Cas9 endonuclease). In some embodiments, an RNA-guided endonuclease as described herein targets a specific DNA sequence in a target DNA through an RNA molecule to which it binds. The RNA molecule may include a sequence that is complementary to a target sequence within the target DNA and is capable of hybridizing with the target sequence, thereby allowing the bound polypeptide to be targeted to a specific location within the target DNA.

[0041] As used herein, the term "guide RNA" or "gRNA" refers to a site-specific targeting RNA that can bind to an RNA-guided endonuclease to form a complex and direct the activity of the bound RNA-guided endonuclease (such as a Cas endonuclease) to a specific target sequence within a target nucleic acid. A guide RNA can include one or more RNA molecules.

[0042] As used herein, the "secondary structure" of a nucleic acid molecule (e.g., an RNA fragment or a gRNA) refers to the base pairing interactions within the nucleic acid molecule.

[0043] As used herein, the term "target DNA" refers to a DNA including a "target site" or a "target sequence". The term "target sequence" is used herein to refer to a nucleic acid sequence present in a target DNA to which a DNA targeting sequence or segment (also referred to herein as a "spacer") of a gRNA can hybridize as long as there are sufficient hybridization conditions. For example, a target sequence 5'-GAGCATATC-3' in a target DNA is targeted (or can hybridize or be complementary to it) by an RNA sequence 5'-GAUAUGCUC-3'. The hybridization between the DNA targeting sequence or segment of a gRNA and a target sequence can be, for example, based on the Watson-Crick base pairing rules, which makes programmability in a DNA targeting sequence or segment possible. A DNA targeting sequence or segment of a gRNA can be designed, for example, to hybridize with any target sequence.

[0044] As used herein, the term "Cas endonuclease" or "Cas nuclease" refers to an RNA-guided DNA endonuclease associated with the CRISPR adaptive immune system.

[0045] Unless otherwise indicated, "nuclease" and "endonuclease" are used interchangeably herein to refer to an enzyme with endonucleolytic catalytic activity for polynucleotide cleavage.

[0046] As used herein, the term "constant region" of gRNA refers to the nucleotide sequence of gRNA associated with the endonuclease guided by RNA. In some embodiments, gRNA includes crRNA and trans-activating crRNA (tracrRNA), wherein crRNA and tracrRNA hybridize with each other to form a duplex. In some embodiments, crRNA includes 5' to 3': spacer sequence and minimal CRISPR repeat sequence (also referred to herein as "crRNA repeat sequence"); and tracrRNA includes a minimal tracrRNA sequence complementary to the minimal CRISPR repeat sequence (also referred to herein as "tracrRNA antisense repeat sequence") and 3'tracrRNA sequence. In some embodiments, the constant region of gRNA refers to the part of crRNA that is the minimal CRISPR repeat sequence and tracrRNA.

[0047] As used herein, the term "donor template" refers to a nucleic acid chain containing exogenous genetic material that can be introduced into the genome (e.g., by homology-directed repair) to cause targeted integration of the exogenous genetic material. In some embodiments, the donor template may not have a region homologous to the target position in the DNA, but can be integrated by NHEJ-dependent end connection after cleavage at the target site. The donor template can be single-stranded or double-stranded DNA or RNA, and can be introduced into the cell in a linear or circular form.

[0048] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. A polynucleotide may be single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids / triple helices, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derivatized nucleotide bases.

[0049] As used herein, the term "binding" refers to a non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). When in a non-covalent interaction state, the macromolecules are said to be "associated" or "interacting" or "bound" (e.g., when molecule X is said to interact with molecule Y, this means that molecule X binds to molecule Y in a non-covalent manner). The binding interaction can be characterized by a dissociation constant (Kd), such as a Kd of or less than: 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, 10-13 M, 10 -14 M, 10 -15 M or a number or range between any two of these values. Kd may depend on environmental conditions, such as pH and temperature. "Affinity" refers to the strength of binding, and increased binding affinity is associated with a lower Kd.

[0050] As used herein, the term "hybridizing" or "hybridize" refers to the pairing of substantially complementary or complementary nucleic acid sequences within two different molecules. Pairing can be achieved by any process in which a nucleic acid sequence is joined to a substantially complementary or fully complementary sequence by base pairing to form a hybrid complex. "Hybridizing" or "hybridizing" can include denaturing a molecule to destroy one or more intramolecular structures (e.g., one or more secondary structures) in the molecule. In some embodiments, denaturing the molecule includes heating a solution containing the molecule to a temperature sufficient to destroy the intramolecular structure of the molecule. In some cases, denaturing the molecule includes adjusting the pH of the solution containing the molecule to a pH sufficient to destroy the intramolecular structure of the molecule. For the purpose of hybridization, if at least 80% of the individual bases of two nucleic acid sequences or sequence segments are complementary to each other, they are "substantially complementary". In some embodiments, the splint oligonucleotide sequence is no more than about 50% identical to one of the two polynucleotides (e.g., RNA fragments) designed to be complementary thereto. The complementary portions of each sequence may be referred to herein as "segments," and if the segments have 80% or greater identity, the segments are substantially complementary.

[0051] The terms "complementary" and "complementary" refer to the fact that a nucleic acid can form hydrogen bonds with another nucleic acid based on the traditional Watson-Crick base pairing rules, i.e., adenine (A) pairs with thymine (U), and guanine (G) pairs with cytosine (C). Complementarity can be complete (e.g., complete complementarity) or incomplete (e.g., partial complementarity). Complete or complete complementarity indicates that each and all nucleic acid bases of a chain can form hydrogen bonds with the corresponding bases in another antiparallel nucleic acid sequence according to the Watson-Crick standard base pairing. Partial complementarity means that only a certain percentage of continuous residues in a nucleic acid sequence can form Watson-Crick base pairing with the same number of continuous residues in another antiparallel nucleic acid sequence. In some embodiments, complementarity can be at least 70%, 80%, 90%, 100%, or a number or range between any two of these values. In some embodiments, complementarity is complete, i.e., 100%. For example, the complementary candidate sequence segment is completely complementary to the candidate sequence segment, and the sequence of the candidate sequence segment can be deduced from the candidate sequence segment using Watson-Crick base pairing rules.

[0052] As used herein, the term "vector" refers to a polynucleotide construct, typically a plasmid or a virus, for delivering genetic material to a host cell. A vector may be, for example, a virus, a plasmid, a cosmid, or a bacteriophage. A vector as used herein may include DNA or RNA. In some embodiments, a vector includes DNA. An "expression vector" is a vector that can direct the expression of a protein encoded by one or more genes carried by the vector when it is present in an appropriate environment. The vector is preferably capable of autonomous replication. Typically, an expression vector comprises a transcriptional promoter, a gene, and a transcriptional terminator. Gene expression is typically placed under the control of a promoter, and a gene is referred to as being "operably connected" to a promoter.

[0053] As used herein, the terms "nucleic acid" and "polynucleotide" are interchangeable and refer to any nucleic acid, whether comprising phosphodiester linkages or modified linkages such as phosphotriester, phosphoramide, siloxane, carbonate, carboxymethyl ester, acetamide, carbamate, thioether, bridged phosphoramide, bridged methylenephosphonate, bridged phosphoramide, bridged phosphoramide, bridged methylenephosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sultone linkages, and combinations of such linkages. The terms "nucleic acid" and "polynucleotide" also specifically include nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).

[0054] As used herein, the term "transfection" or "infection" refers to the introduction of nucleic acid into a host cell, such as by contacting the cell with a recombinant MVA virus or gutless picornaviral particles as described herein.

[0055] As used herein, the term "transgenic" refers to any nucleotide or DNA sequence that is integrated into one or more chromosomes of a target cell by human intervention. In some embodiments, the transgenic comprises a polynucleotide encoding a protein of interest. The polynucleotide encoding the protein is usually operably linked to other sequences that can be used to obtain the desired expression of the gene of interest, such as a transcriptional regulatory sequence. In some embodiments, the transgenic may additionally comprise a nucleic acid or one or more other molecules for marking the chromosome into which it has been integrated.

[0056] As used herein, "treatment" refers to clinical intervention for a disease, disorder, or physiological condition that a patient exhibits or to which the patient may be susceptible. The purposes of treatment include, but are not limited to, alleviating or preventing symptoms, slowing or stopping the progression or worsening of a disease, disorder, or condition, and / or alleviating a disease, disorder, or condition. "Treatment" refers to one or both of therapeutic treatment and prophylactic or preventive measures. Subjects in need of treatment include those already affected by a disease, disorder, or undesirable physiological condition, as well as those for whom a disease, disorder, or undesirable physiological condition is to be prevented.

[0057] As used herein, the term "effective amount" or "pharmaceutically effective amount" or "therapeutically effective amount" refers to an amount sufficient to produce beneficial or desired biological and / or clinical results.

[0058] As used herein, the term "pharmaceutically acceptable excipient" refers to any suitable substance that provides a pharmaceutically acceptable carrier, additive, or diluent for administering a compound of interest to a subject. Pharmaceutically acceptable excipients may include substances known as pharmaceutically acceptable diluents, pharmaceutically acceptable additives, and pharmaceutically acceptable carriers.

[0059] As used herein, "subject" refers to an animal that needs diagnosis, treatment or therapy. In some embodiments, the subject is a mammal. "Mammal" as used herein refers to an individual belonging to the class of mammals, and includes but is not limited to humans, livestock and farm animals, zoo animals, sports animals and pets. Non-limiting examples of mammals include mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cattle; horses; primates, such as monkeys, chimpanzees and apes, and particularly humans. In some embodiments, mammals are primates. In some embodiments, mammals are humans. In some embodiments, mammals are not humans. In some aspects, the subject may suffer from or be suspected of having cardiovascular disease and / or have one or more symptoms of cardiovascular disease. In some aspects, the subject is a human being diagnosed as having a risk of cardiovascular disease at or after diagnosis. In some cases, the diagnosis of cardiovascular disease risk can be determined based on the presence of one or more mutations that may affect apo (a) protein expression in the genome sequence near the endogenous apolipoprotein (a) (LPA) gene or LPA gene in the genome.

[0060]

[00136] The term "plasma level" as used herein in the context of a molecule refers to the concentration or amount of the molecule, eg, the number of moles or weight of the molecule present in a given volume of plasma.

[0061] High levels of Lp (a) are associated with increased risk of cardiovascular disease. Lp (a) levels greater than 50 mg / dL can cause calcific aortic valve disease (CAVD) and cardiovascular disease (CVD). Unlike low-density lipoprotein, Lp (a) levels cannot be regulated by the environment, diet, exercise or existing lipid-lowering drugs such as statins, making it a genetically driven disease risk factor. There is a need for new gene therapies that can stably reduce Lp (a) levels or permanently reduce Lp (a) levels over an extended period of time. The present disclosure provides a highly effective gene editing method and related compositions and kits that directly target LPA genes or their variants to permanently knock out LPA genes from the genome to permanently reduce Lp (a) levels in the subject's blood (e.g., plasma). In some embodiments, the methods, compositions and kits described herein can reduce plasma Lp (a) levels by at least 20%, at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80% or more. In some embodiments, after implementing the method, the plasma Lp(a) level in the subject is reduced to or to about 60 mg / dL, 55 mg / dL, 50 mg / dL, 45 mg / dL, 40 mg / dL, 35 mg / dL, 30 mg / dL or less. The gRNA sequences described herein can also significantly minimize the number and frequency of off-target effects, thereby reducing the risk of genotoxicity. The methods, compositions, and kits described herein can be used to treat cardiovascular disease in a subject and / or reduce the risk of cardiovascular disease.

[0062] Lipoprotein(a) (Lp(a)) Provided herein are vectors, compositions, methods, systems and kits for editing the LPA gene encoding apolipoprotein (a) protein of lipoprotein (a) (Lp (a)) in the genome of a cell (including, for example, LPA gene variants associated with increased risk of cardiovascular disease and / or increased expression of Lp (a)) to modulate (e.g., reduce) the expression, function or activity of Lp (a) in the cell. As used herein, the term "LPA gene" includes genomic regions encompassing LPA regulatory promoter and enhancer sequences as well as LPA coding sequences.

[0063] Lp(a) is an atherogenic lipoprotein composed of the protein apolipoprotein(a) (apo(a)) covalently bound to the apolipoprotein B-100 (apoB) component of low-density lipoprotein (LDL) particles (see e.g. Figure 1). The apo(a) protein is encoded by the LPA gene, produced in hepatocytes and secreted into the circulation. However, while it is known that apo(a) docks with LDL and forms a covalent disulfide bond with apoB to become Lp(a), the precise site of Lp(a) assembly is unknown. This binding of apo(a) to apoB blocks the LDL receptor binding site of apoB and, therefore, prevents clearance via the LDL receptor pathway. apo(a) evolved from the plasminogen gene and contains related protein domains. The apo(a) protein includes a kringle V (KV) domain, multiple copies of the kringle IV (KIV) domain, and an inactive protease-like domain, all of which are derived from plasminogen. KIV is broken down into 10 isoforms, with KIVi and KIV3-10 present in 1 copy and KIV2 present in 1 to greater than 40 copies. The size of apo(a) varies between individual humans and is proportional to the number of copies of KIV2, which is genetically determined. Plasma levels of Lp(a) are inversely correlated with the size of the apo(a) protein, and this is thought to be due to the slower secretion of the larger isoform. High plasma levels of Lp(a) are an independent risk factor for many cardiovascular diseases, including calcific aortic valve disease, coronary heart disease, atherosclerosis, thrombosis, and stroke (reviewed in: Kronenberg, F. (2016). Cardiovasc. Drugs Ther., 30(l):87-100).

[0064] The pathogenic mechanism of Lp(a) is mediated by its pro-atherosclerotic, pro-inflammatory and pro-thrombotic properties. The combination of the LDL components of apo(a) and Lp(a) results in a compound effect on the cardiovascular system. LDL alone can enter the vessel wall through the LDL, where the phospholipids become oxidized, causing the immune and inflammatory responses that characterize atherosclerosis. Lp(a) circulates and binds to oxidized phospholipids in the plasma, causing a pro-inflammatory response. Apo(a) itself contains sites that can bind to exposed surfaces on damaged vessel walls, mediating its entry and accumulation at these locations. Small isoforms of apo(a) have been shown to promote thrombosis by inhibiting fibrinolysis.

[0065] The relationship between plasma Lp(a) levels and cardiovascular disease has been extensively examined, and multiple studies have positively correlated high Lp(a) levels with a higher risk of cardiovascular disease (reviewed in: Kronenberg, F. (2016). Cardiovasc. Drugs Ther., 30(l):87-100). The range of human plasma Lp(a) levels can vary 1000-fold between individuals (e.g., from 0.1 mg / dL to >300 mg / dL or from <30 nmol / L to >400 nmol / L). Variable serum levels are genetically determined by, for example, Apo(a) allele size (number of KIV-2 repeats), 5' pentanucleotide repeat polymorphisms, SNPs in the 5' and other regions of the LPA gene. Lp(a) levels in serum can be detected using an ELISA assay or immunoturbidometric analysis, as will be appreciated by those skilled in the art.

[0066] The LPA gene (also known as LP, AK38, and APOA) has a cytogenetic location of 6q25.3-q26 and genomic coordinates at positions 160531482-160664275 on the reverse strand of chromosome 6. The nucleotide sequence of LPA can be found on the NCBI website, NCBI reference sequence: NC_000006.12. The NCBI gene ID of LPA is 4018, the Uniprot ID is P08519, and the Ensembl gene ID is ENSG00000198670.

[0067] Gene Editing Provided herein are methods, compositions and kits for editing the LPA gene or its variants to reduce the expression level of Lp(a) in a subject (e.g., plasma concentration of Lp(a)).Gene editing (including genome editing) is a type of genetic engineering in which one or more nucleotides / one or more nucleic acids are inserted, deleted and / or replaced in a DNA sequence (such as in the genome of a target cell). Targeted gene editing enables insertion, deletion and / or replacement at a preselected site in the genome of a target cell (e.g., in a targeted gene or a targeted DNA sequence). When the sequence of an endogenous gene is edited, for example, by deletion, insertion or replacement of one or more nucleotides / one or more nucleic acids, the endogenous gene containing the affected sequence can be knocked out or knocked down due to sequence changes. Therefore, targeted editing can be used to destroy endogenous gene expression. "Targeted integration" refers to a process involving the insertion of one or more exogenous sequences, with or without the deletion of endogenous sequences at the insertion site. When there is a donor template containing an exogenous sequence, targeted integration can be produced by targeted gene editing.

[0068] Targeted editing can be achieved by nuclease-independent methods or by nuclease-dependent methods. In nuclease-independent targeted editing methods, homologous recombination is guided by homologous sequences flanking the exogenous polynucleotide to introduce endogenous sequences through the enzymatic machinery of the host cell. The exogenous polynucleotide can introduce deletions, insertions, or substitutions of nucleotides in the endogenous sequence.

[0069] Alternatively, the nuclease-dependent method can specifically introduce double-strand breaks (DSBs) by specific rare cutting nucleases (e.g., endonucleases) to achieve targeted editing with higher frequency. Such nuclease-dependent targeted editing also utilizes DNA repair mechanisms, such as non-homologous end joining (NHEJ) that occurs in response to DSB. DNA repair by NHEJ generally results in random insertion or deletion (insertion / deletion (indel)) of a small amount of endogenous nucleotides. Compared with the repair mediated by NHEJ, repair can also occur by homology-directed repair (HDR). When there is a donor template containing an exogenous genetic material flanked by a pair of homology arms, the exogenous genetic material can be introduced into the genome by HDR, which results in targeted integration of the exogenous genetic material.

[0070] Available endonucleases capable of introducing specific and targeted DSBs include, but are not limited to, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and RNA-guided CRISPR-Cas9 nucleases (CRISPR / Cas9; clustered regularly interspaced short palindromic repeats-related 9). Additionally, the DICE (Dual Integrase Cassette Exchange) system utilizing phiC31 and Bxb1 integrases can also be used for targeted integration.

[0071] ZFN is a targeted nuclease comprising a nuclease fused to a zinc finger DNA binding domain (ZFBD), which is a polypeptide domain that binds DNA in a sequence-specific manner through one or more zinc fingers. A zinc finger is a domain of about 30 amino acids within a zinc finger binding domain whose structure is stabilized by the coordination of zinc ions. Examples of zinc fingers include, but are not limited to, C2H2 zinc fingers, C3H zinc fingers, and C4 zinc fingers. A designed zinc finger domain is a domain that does not exist in nature, and its design / composition is primarily derived from rational criteria, e.g., applying substitution rules and computerized algorithms to process information in a database storing information on existing ZFP designs and binding data. See, e.g., U.S. Pat. Nos. 6,140,081; 6,453,242; and 6,534,261; see also WO 98 / 53058; WO 98 / 53059; WO 98 / 53060; WO 02 / 016536 and WO 03 / 016496. The zinc finger domains selected are domains that do not exist in nature and are generated primarily from empirical processes such as phage display, interaction traps, or hybrid selection. ZFNs are described in more detail in U.S. Pat. Nos. 7,888,121 and 7,972,854. The most recognized example of a ZFN is a fusion of a FokI nuclease with a zinc finger DNA binding domain.

[0072] TALEN is a targeted nuclease comprising a nuclease fused to a TAL effector DNA binding domain. A "transcription activator-like effector DNA binding domain", "TAL effector DNA binding domain" or "TALE DNA binding domain" is a polypeptide domain of a TAL effector protein that is responsible for binding of the TAL effector protein to DNA. TAL effector proteins are secreted by plant pathogens of the genus Xanthomonas during infection. These proteins enter the nucleus of plant cells, bind effector-specific DNA sequences via their DNA binding domains, and activate gene transcription of these sequences via their transactivation domains. TAL effector DNA binding domain specificity depends on the effector-variable number of incomplete 34 amino acid repeats, which contain polymorphisms at select repeat positions called repeat variable diresidues (RVDs). TALEN is described in more detail in U.S. Patent Application No. 2011 / 0145940. The most recognized example of TALEN in the art is a fusion polypeptide of the FokI nuclease and the TAL effector DNA binding domain.

[0073] Additional examples of targeted nucleases suitable for use as provided herein include, but are not limited to, Bxb1, phiC31, R4, PhiBT1, and Wβ / SPBc / TP901-1, whether used alone or in combination.

[0074] Other non-limiting examples of targeting nucleases include naturally occurring and recombinant nucleases, such as CRISPR / Cas9, restriction endonucleases, meganucleases, homing endonucleases, and the like.

[0075] CRISPR-Cas gene editing system and RNA-guided nucleases In some embodiments, the vectors, compositions, methods and kits described herein can be used in gene editing systems, such as CRISPR-Cas gene editing systems, to genetically edit LPA genes. For example, the CRISPR-Cas9 system is a naturally occurring defense mechanism in prokaryotes, and has been reused as a DNA targeting platform for RNA guidance for gene editing. The CRISPR-Cas9 system relies on DNA nuclease Cas9 and two non-coding RNAs-crisprRNA (crRNA) and trans-activating RNA (tracrRNA) to target DNA cleavage. CrRNA drives the sequence recognition and specificity of the CRISPR-Cas9 complex by Watson-Crick base pairing of 20 nucleotides (nt) sequences in the target DNA. If the target sequence is followed by a specific short DNA motif (having a sequence NGG) called a protospacer adjacent motif (PAM), the CRISPR-Cas9 complex only binds to a DNA sequence containing a sequence matching the first 20 nt of crRNA and a single guide RNA (sgRNA). TracrRNA hybridizes with the 3' end of crRNA to form an RNA duplex structure, which is bound by the Cas9 endonuclease to form a catalytically active CRISPR-Cas9 complex, which can then cleave the target DNA. After the CRISPR-Cas9 complex binds to DNA at the target site, the two independent nuclease domains in the Cas9 enzyme each cleave one of the DNA chains upstream of the PAM site, leaving a double-strand break (DSB), where the two chains of DNA terminate in base pairs (flat ends). After the CRISPR-Cas9 complex binds to DNA at a specific target site and forms a site-specific DSB, the next key step is the repair of DSB. Cells use two major DNA repair pathways to repair DSB: non-homologous end joining (NHEJ) and homology-directed repair (HDR). In some embodiments, the CRISPR-Cas9 gene editing system comprises an RNA-guided nuclease and one or more guide RNAs targeting one or more target genes.

[0076] As described herein, RNA-guided endonucleases can be naturally occurring or non-naturally occurring. Non-limiting examples of RNA-guided endonucleases include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonucleases and functional derivatives thereof. In some cases, the RNA-guided endonuclease is a Cas9 endonuclease. The Cas9 endonuclease can be, for example, Streptococcus pyogenes (SpyCas9), Staphylococcus lugdunensis (SluCas9), P. Pneumotropica Cas9 (PpCas9), Staphylococcus auricularis Cas9 (SauriCas9), Staphylococcus lutrae Cas9 (SlutrCas9), Staphylococcus haemolyticus Cas9 (ShaCas9), Campylobacter jejuni (CjCas9), Staphylococcus aureus (Staphylococcus aureus) (SaCas9), or variants thereof. In some embodiments, the RNA-guided endonuclease is a variant of Cas9, including but not limited to small Cas9, dead Cas9 (dCas9) and Cas9 nickase. In some embodiments, the Cas nuclease may include a RuvC or RuvC-like nuclease domain (e.g., Cpf1) and / or a HNH or HNH-like nuclease domain (e.g., Cas9). In some embodiments, the Cas9 endonuclease is Streptococcus pyogenes Cas9, Staphylococcus aureus Cas9, Neisseria meningitidis Cas9, Streptococcus thermophilus Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola Cas9 or a variant thereof.

[0077] The RNA-guided endonuclease can be a small RNA-guided endonuclease. The small RNA-guided endonuclease can be engineered from a portion of an RNA-guided endonuclease derived from any RNA-guided endonuclease described herein and known in the art. The small RNA-guided endonuclease can be, for example, a small Cas endonuclease. In some cases, the length of the small RNA-guided nuclease is shorter than about 1,100 amino acids.

[0078] The RNA-guided endonuclease can be a mutant RNA-guided endonuclease. For example, the RNA-guided endonuclease can be a mutant of a naturally occurring RNA-guided endonuclease. The mutated RNA-guided endonuclease can also be a mutated RNA-guided endonuclease with a changed activity compared to a naturally occurring RNA-guided endonuclease, such as a changed endonuclease activity (e.g., a changed or eliminated DNA endonuclease activity, while the binding affinity to DNA is not substantially weakened). Such modifications can allow sequence-specific DNA targeting of the mutant RNA-guided endonuclease for the following purposes: transcriptional regulation (e.g., activation or repression); epigenetic modification or chromatin modification by methylation, demethylation, acetylation or deacetylation, or any other modification of DNA binding and / or DNA-modifying proteins known in the art. In some embodiments, the mutant RNA-guided endonuclease does not have DNA endonuclease activity.

[0079] The RNA-guided endonuclease can be a nickase that cleaves the complementary strand of the target DNA but has a reduced ability to cleave the non-complementary strand of the target DNA, or a nickase that cleaves the non-complementary strand of the target DNA but has a reduced ability to cleave the complementary strand of the target DNA. In some embodiments, the RNA-guided endonuclease has a reduced ability to cleave both the complementary and non-complementary strands of the target DNA.

[0080] In some embodiments, a nucleic acid encoding an endonuclease guided by RNA is administered to a subject. In some embodiments, nucleic acid can be produced by an in vitro transcription reaction. In some embodiments, the production of in vitro transcribed RNA includes incubating a linear DNA template with an RNA polymerase and a nucleotide mixture under conditions that allow (run-off) RNA in vitro transcription. The nucleotide mixture can be a part of an in vitro transcription mixture (IVT-mix). In some embodiments, the RNA polymerase is a T7 RNA polymerase. The nucleotide mixture used for RNA in vitro transcription can additionally contain modified nucleotides defined as follows. In some embodiments, the nucleotide mixture (e.g., the ratio of each nucleotide in the mixture) (optimized NTP mixture) for RNA in vitro transcription reaction can be optimized for a given RNA sequence. Such a method is described in, for example, WO2015 / 188933. In some embodiments, the RNA obtained by using the method of an optimized NTP mixture is characterized by reduced immunostimulatory properties.

[0081] In some embodiments, the nucleotide mixture comprises unmodified ribonucleoside triphosphates (NTPs) GTP, ATP, CTP, and UTP. In some embodiments, in vitro transcription may include the presence of at least one cap analog, such as cap 1 (cap1) trinucleotide cap analog, m7G (5') ppp (5') (2'OMeA) pG or m7G (5') ppp (5') (2'OMeG) pG, m7G (5') ppp (5') (2'OMeA) pG or rn7 (3'OMeG) (5') ppp (5') (2'OMeA) pG. In some embodiments, the 5'-cap structure is formed via enzymatic capping using a capping enzyme (e.g., vaccinia virus capping enzyme and / or cap-dependent 2'-O-methyltransferase) to produce cap 0 or cap 1 or cap 2 structures. The methods and means disclosed in WO2016 / 193226 can also be used to add a 5'-cap structure (cap 0 or cap 1) using a fixed capping enzyme and / or a cap-dependent 2'-O-methyltransferase. In some embodiments, a portion or all of at least one (ribose) nucleoside triphosphate is replaced by a modified nucleoside triphosphate. In some embodiments, the modified nucleoside triphosphate includes pseudouridine (ψ), N1-methylpseudouridine (m1 ψ), 5-methylcytosine, or 5-methoxyuridine. In some embodiments, the uracil nucleotides in the nucleotide mixture are replaced (partially or completely) by pseudouridine (ψ) and / or N1-methylpseudouridine (m1 ψ) to obtain modified RNA. In some embodiments, the chemically modified nucleotide is pseudouridine (ψ). In some embodiments, the chemically modified nucleotide is N1-methylpseudouridine (m1 ψ). In some embodiments, the nucleotide mixture comprises at least one modified nucleotide and / or at least one nucleotide analog or nucleotide derivative for incorporation into RNA. For example, the nucleotide of modification as defined herein can include nucleotide analogs / modifications, such as backbone modifications, sugar modifications or base modifications. The backbone modification can include modifications in which the phosphoric acid of the nucleotide backbone is chemically modified. Sugar modifications can include chemical modifications of the sugar of the nucleotide. In addition, base modifications can include chemical modifications of the base moiety of the nucleotide. In this context, nucleotide analogs or modifications can include nucleotide analogs suitable for transcription and / or translation. In some embodiments, the nucleotide mixture comprises at least one modified nucleotide and / or at least one nucleotide analog selected from the nucleotides of the backbone modification, sugar-modified nucleotides and / or base-modified nucleotides or any combination thereof.

[0082] Modified nucleosides and nucleotides that can be included in nucleotide mixtures and incorporated into RNA can be modified in the sugar moiety. For example, the 2' hydroxyl group (OH) can be modified or replaced by many different "oxy" or "deoxy" substituents. Examples of "oxy"-2' hydroxyl group modifications include, but are not limited to, alkoxy or aryloxy (-OR, such as R = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar); polyethylene glycol (PEG), -O(CH2CH 20 )nCH2CH2OR; a "locked" nucleic acid (LNA) in which the 2' hydroxyl group is connected to the 4' carbon of the same ribose, for example, by a methylene bridge; and an amino group (-O-amino, wherein the amino group can be alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine, polyamino) or aminoalkoxy. "Deoxy" modifications include hydrogen, amino (e.g., NH2, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino or amino acid); or the amino group can be connected to the sugar through a linker, wherein the linker contains one or more of the atoms C, N and O. The glycosyl group can also contain one or more carbons with a stereochemical configuration relative to the corresponding carbon in the ribose. Thus, the modified RNA molecule can include nucleotides containing, for example, arabinose as a sugar.

[0083] The phosphate backbone can be further modified in the nucleosides and nucleotides of modification, which can be included in the nucleotide mixture and incorporated in the RNA of the in vitro transcription of modification. The phosphate group of the main chain can be modified by replacing one or more oxygen atoms with different substituents. In addition, the nucleosides and nucleotides of modification can include the phosphoric acid with the modified phosphoric acid as described herein to completely replace the unmodified phosphate moiety. The example of the phosphate group of modification includes but is not limited to phosphorothioate, selenophosphate (phosphoroselenates), boranophosphates (borano phosphates), boranophosphate esters (boranophosphate esters), hydrogen phosphonate, phosphoramidate, alkyl or aryl phosphonate and phosphotriester. Two non-connected oxygens of dithiophosphate are replaced by sulfur. Phosphate joints can also be modified by replacing connected oxygen with nitrogen (phosphoramidate of bridge joint), sulfur (phosphorothioate of bridge joint) and carbon (methylene-phosphonate of bridge joint).

[0084] Nucleotides as described herein can be modified in the nucleobase portion. Examples of nucleobases present in RNA include, but are not limited to, adenine, guanine, cytosine, and uracil. For example, nucleosides and nucleotides described herein can be chemically modified on the major groove surface. In some embodiments, the major groove chemical modification includes an amino group, a thiol group, an alkyl group, or a halogen group.

[0085] Nucleotide analogs / modifications may include 2-amino-6-chloropurine riboside-5'-triphosphate, 2-aminopurine-riboside-5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-amino-2'-deoxycytidine-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-fluorothymidine-5'-triphosphate, 2'-O-methyl-inosine-5'-triphosphate, 4-thiouridine -5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-iodouridine-5'-triphosphate , 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxyuridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine riboside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate, 7- Deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-riboside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, puromycin-5'-triphosphate, xanthosine-5'-triphosphate. The base modified nucleotides may include 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate and pseudouridine-5'-triphosphate, pyridine-4-ketone ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl ur ... sulfonic acid methyl-2-thio-uridine, 1-taurine methyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thiodihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine,3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine glycosides, 4-methoxy-pseudoisocytidine and 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N 6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine and N2,N2-dimethyl-6-thio-guanosine, 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine, 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, 5'-O-(1-thiophosphate)-pseudouridine, 6-aza-cytidine, 2-thio-cytidine, α-thio-cytidine, pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine, α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, pyrrolo-cytidine, inosine, α-thio-guanosine, 6-methyl-guanosine,5-methyl-cytidine, 8-oxo-guanosine, 7-deaza-guanosine, N1-methyl-adenosine, 2-amino-6-chloro-purine, N6-methyl-2-amino-purine, pseudo-iso-cytidine, 6-chloro-purine, N6-methyl-adenosine, α-thio-adenosine, 8-azido-adenosine or 7-deaza-adenosine.

[0086] At least one modified nucleotide and / or at least one nucleotide analog described herein may include 1-methyladenosine, 2-methyladenosine, N6-methyladenosine, 2'-O-methyladenosine, 2-methylthio-N6-methyladenosine, N6-isopentenyladenosine, 2-methylthio-N6-isopentenyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, N6-hydroxynorvalylcarbamoyladenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyladenosine, inosine, 3-methylcytidine, 2-O-methylcytidine, 2-thiocytidine, N4-acetylcytidine, lysine, 1-methylguanosine, 7-methylguanosine, 2'-O-methylguanosine, braided glycoside, epoxy braided glycoside, 7-cyano-7-deaza Guanosine, 7-aminomethyl-7-deazaguanosine, pseudouridine, dihydrouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, 4-thiouridine, 5-methyl-2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 5'-hydroxyuridine, 5-methoxyuridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-aminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethylaminomethyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine or 5-(isopentenylaminomethyl)-2'-O-methyluridine.

[0087] In some embodiments, the chemical modification includes pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, 2'-O-methyluridine, or a combination thereof.

[0088] In some embodiments, 100% of the uracil in the coding sequence can have chemical modification. In some embodiments, the chemical modification is in the 5'-position of uracil. In some embodiments, 100% of the uracil in the coding sequence (cds) of RNA can have chemical modification, such as chemical modification in the 5' position of uracil. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the uracil nucleotides in cds have chemical modification, such as chemical modification in the 5-position of the uracil nucleotides. Such modification can reduce the stimulation to the innate immune system (after the RNA comprising such modified nucleotides is used in vivo).

[0089] The term "cds" or "coding sequence" or "coding region" as used herein will be recognized and understood by those of ordinary skill in the art, and may refer, for example, to a sequence of several nucleotide triplets that can be translated into a peptide or protein. The cds of the RNA may contain at least one modified nucleotide, wherein the at least one modified nucleotide may be selected from pseudouridine (ψ), N1-methyl pseudouridine (m1 ψ), 5-methylcytosine and 5-methoxyuridine.

[0090] As used herein, the term "modified nucleotides" or "chemically modified nucleotides" may refer to all potential natural and non-natural chemical modifications of the building blocks of RNA (ie, ribonucleotides A, G, C, and U).

[0091] In some embodiments, the nucleotide mixture in the in vitro transcription reaction includes a cap analog. Therefore, in some embodiments, the cap analog is cap 0, cap 1, cap 2, modified cap 0 or modified cap 1 analog or cap 1 analog as described below. The term "cap analog" or "5'-cap structure" used herein may refer to the 5' structure of RNA, particularly the guanine nucleotide at the 5' end of RNA (e.g., mRNA). In some embodiments, the 5'-cap structure is connected to RNA via a 5'-5'-triphosphate bond. In some embodiments, "5'-cap structure" or "cap analog" is not considered to be a "modified nucleotide" or "chemically modified nucleotide". Potentially suitable 5'-cap structures include cap 0 (methylation of the first nucleobase, such as m7GpppN), cap 1 (additional methylation of the ribose of the adjacent nucleotide to m7GpppN), cap 2 (additional methylation of the ribose of the second nucleotide downstream of m7GpppN), cap 3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), cap 4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN), ARCA (antisense reverse cap analog), modARCA (e.g., phosphorothioate modARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine.

[0092] The 5'-cap (cap 0 or cap 1) structure can be formed using a capping enzyme in chemical RNA synthesis, or using a cap analog in RNA in vitro transcription (co-transcriptional capping). As used herein, the term "cap analog" may refer to a non-polymerizable dinucleotide or trinucleotide having a cap functional group, because when incorporated at the 5' end of the RNA, the cap analog promotes translation or localization of the RNA and / or prevents degradation of the RNA. Non-polymerizable means that the cap analog will only be incorporated at the 5' end because it does not have a 5' triphosphate and therefore cannot be extended in the 3' direction by a template-dependent polymerase (e.g., a DNA-dependent RNA polymerase). Examples of cap analogs include m7GpppG, m7GpppA, m7GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analogs (e.g., m2,7GpppG), trimethylated cap analogs (e.g., m2,2,7GpppG), dimethylated symmetric cap analogs (e.g., m7Gpppm7G) or antisense reverse cap analogs (e.g., ARCA; m7,2'OmeGpppG, m7,2'dGpppG, m7,3'OmeGpppG, m7,3'dGpppG and tetraphosphate derivatives thereof). Additional cap analogs have been described previously, e.g., in WO2008 / 016473, WO2008 / 157688, WO2009 / 149253, WO2011 / 015347 and WO2013 / 059475. Further suitable cap analogs in this context are described, for example, in WO2017 / 066793, WO2017 / 066781, WO2017 / 066791, WO2017 / 066789, WO2017 / 053297, WO2017 / 066782, WO2018 / 075827 and WO2017 / 066797, the disclosures relating to cap analogs being incorporated herein by reference.

[0093] In some embodiments, the cap 1 structure is generated using a trinucleotide cap analog as disclosed in WO2017 / 053297, WO2017 / 066793, WO2017 / 066781, WO2017 / 066791, WO2017 / 066789, WO2017 / 066782, WO2018 / 075827, and WO2017 / 066797. For example, any cap analog that can be derived from the structure disclosed in claims 1-5 of WO2017 / 053297 can be suitably used to co-transcriptionally generate the cap 1 structure. In some embodiments, any cap analog that can be derived from the structure described in WO2018 / 075827 can be suitably used to co-transcriptionally generate the cap 1 structure. In some embodiments, the cap 1 analog is a cap 1 trinucleotide cap analog. In some embodiments, the cap 1 structure of the in vitro transcribed RNA is formed using co-transcriptional capping using the trinucleotide cap analog m7G(5')ppp(5')(2'OMeA)pG or m7G(5')ppp(5')(2'OMeG)pG. In some embodiments, the cap 1 analog is m7G(5')ppp(5')(2'OMeA)pG.

[0094] In some embodiments, RNA (e.g., mRNA) comprises a 5'-cap structure, such as a cap 1 structure. In some embodiments, the 5' cap structure can improve the stability and / or expression of mRNA. The cap 1 structure comprising mRNA (generated by, for example, in vitro transcription) has several advantageous features, including increased translation efficiency and reduced stimulation of the innate immune system. In some embodiments, the in vitro transcribed RNA comprises at least one coding sequence encoding at least one peptide or protein. In some embodiments, the protein is an RNA-guided endonuclease. In some embodiments, the RNA-guided endonuclease is Cas9 or a derivative thereof.

[0095] The present disclosure provides an optimized mRNA ("SpCas9mRNA") encoding a Streptococcus pyogenes Cas9 endonuclease, and optionally includes chemically modified nucleotides, which provide effective genome editing of a target cell population when administered with one or more gRNAs. In some embodiments, the present disclosure provides an mRNA comprising (i) a 5' untranslated region (UTR); (ii) an open reading frame (ORF) comprising a nucleotide sequence encoding a site-directed endonuclease; and (iii) a 3' untranslated region (UTR). In some embodiments, the site-directed endonuclease is a Cas nuclease. In some embodiments, the Cas nuclease is a Cas9 polypeptide. In some embodiments, the Cas9 polypeptide is a Cas9 (SpCas9) polypeptide derived from Streptococcus pyogenes. In some embodiments, the ORF also comprises one or more nucleotide sequences encoding a nuclear localization signal, such as the nucleotide sequences described herein. In some embodiments, the ORF comprises a nucleotide sequence encoding a site-directed endonuclease (such as a SpCas9 polypeptide) and at least one NLS, which is a nucleoplasmic protein and / or an SV40 NLS. In some embodiments, the ORF comprises a nucleotide sequence encoding an N-terminal and / or C-terminal NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide). In some embodiments, the ORF comprises a nucleotide sequence encoding an N-terminal SV40 NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide) and a C-terminal nucleoplasmic protein NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide).

[0096] In some embodiments, mRNA can include at least one chemically modified nucleoside and / or nucleotide.In some embodiments, the chemically modified nucleoside is selected from pseudouridine, N1-methyl pseudouridine and 5-methoxyuridine.In some embodiments, the chemically modified nucleoside is N1-methyl pseudouridine (e.g., 1-methyl pseudouridine).In some embodiments, at least about 80% or more (e.g., about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) of uridine in mRNA is modified or replaced by N1-methyl pseudouridine.In some embodiments, 100% of uridine (e.g., uracil) in mRNA is modified or replaced by N1-methyl pseudouridine. In some embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 4, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800 or more) is N1-methylpseudouridine.

[0097] Guide RNA (gRNA) In some embodiments, the CRISPR / Cas-mediated gene editing system for genetically editing the LPA gene comprises a genome targeting nucleic acid (e.g., a guide RNA) that can guide the activity of the RNA-guided endonuclease to a specific target sequence within the LPA gene. The guide RNA comprises at least a spacer sequence and a CRISPR repeat sequence hybridized with a target nucleic acid sequence of interest. The gRNA can be a single-molecule guide RNA or a double-molecule guide RNA. The RNA-guided endonuclease can be, for example, a Cas endonuclease, including a Cas9 endonuclease. The Cas9 endonuclease can be, for example, a SpyCas9, SaCas9, or SluCas9 endonuclease. In some embodiments, the RNA-guided endonuclease is a Cas9 variant. In some embodiments, the RNA-guided endonuclease is a small RNA-guided endonuclease. In some embodiments, the RNA-guided endonuclease is a small Cas endonuclease.

[0098] In some embodiments, gRNA comprises 5' to 3': crRNA and tracrRNA, wherein crRNA and tracrRNA hybridize to form a duplex. In some embodiments, crRNA comprises a spacer sequence and a crRNA repeat sequence capable of targeting a target sequence in a target nucleic acid (e.g., a genomic DNA molecule). In some embodiments, tracrRNA comprises a tracrRNA antisense repeat sequence and a 3'tracrRNA sequence. In some embodiments, the 3' end of the crRNA repeat sequence is connected to the 5' end of the tracrRNA antisense repeat sequence, for example, through a tetraloop, wherein the crRNA repeat sequence and the tracrRNA antisense repeat sequence hybridize to form sgRNA. In some embodiments, sgRNA comprises 5' to 3': a spacer sequence, a crRNA repeat sequence, a tetraloop, a tracrRNA antisense repeat sequence, and a 3'tracrRNA sequence. In some embodiments, sgRNA comprises a 5' spacer extension sequence. In some embodiments, sgRNA comprises a 3'tracrRNA extension sequence. 3'tracrRNA may comprise or consist of one or more stem loops, such as one, two, three or more stem loops.

[0099] In some embodiments, the invariant sequence of the sgRNA comprises a nucleotide sequence of GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 1), or a nucleotide sequence having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide deletions, insertions, or substitutions relative to SEQ ID NO: 1. In some embodiments, the sgRNA is used with a SpCa9 or SpyCas9 endonuclease.

[0100] The guide RNA disclosed herein can target any sequence of interest via the spacer sequence in crRNA. The spacer sequence in gRNA is a sequence (e.g., 20 nucleotide sequences) defining a target sequence (e.g., a DNA target sequence, such as a genomic target sequence) of a target gene of interest (e.g., LPA gene). In some embodiments, the range of the spacer sequence is 15 to 30 nucleotides. For example, the length of the spacer sequence can be below, can be about below, can be at least below, or can be at most below: 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50 or any two of these values ​​The number or range of nucleotides. In some embodiments, the spacer sequence contains 20 nucleotides. In some embodiments, gRNA can hybridize with the forward strand of the target dsDNA. In some embodiments, gRNA can hybridize with the reverse strand of the target dsDNA.

[0101] "Target sequence" is in the target gene adjacent to the PAM sequence, and is a sequence to be modified by a nuclease (e.g., Cas9) guided by RNA. "Target sequence" is on the so-called PAM-chain in the "target nucleic acid", and the target nucleic acid is a double-stranded molecule containing a PAM-chain and a complementary non-PAM chain. Those skilled in the art recognize that the gRNA spacer sequence hybridizes with the complementary sequence in the non-PAM chain of the target nucleic acid of interest. Therefore, the gRNA spacer sequence is the RNA equivalent of the target sequence. The spacer of the gRNA interacts with the target nucleic acid of interest in a sequence-specific manner via hybridization (i.e., base pairing). Therefore, the nucleotide sequence of the spacer varies according to the target sequence of the target nucleic acid of interest. In some embodiments, the target sequence of the LPA gene is within exon 3 of the LPA gene.

[0102] In the CRISPR / Cas system used herein, the spacer sequence is designed to hybridize with a region of the target nucleic acid located 5' of a PAM that can be recognized by the Cas9 enzyme used in the system. The spacer can completely match the target sequence or can have a mismatch. Each Cas9 enzyme has a specific PAM sequence that it recognizes in the target DNA. For example, Streptococcus pyogenes Cas9 recognizes a PAM containing the sequence 5'-NRG-3' in the target nucleic acid, where R contains A or G, where N is any nucleotide, and N is immediately adjacent to the 3' of the target nucleic acid sequence targeted by the spacer sequence.

[0103] In some embodiments, the target nucleic acid sequence is 20 nucleotides in length. In some embodiments, the target nucleic acid is less than 20 nucleotides in length. In some embodiments, the target nucleic acid is more than 20 nucleotides in length. In some embodiments, the target nucleic acid is at least: 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides in length. In some embodiments, the target nucleic acid is at most: 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides in length. In some embodiments, the target nucleic acid sequence has 20 bases immediately adjacent to the first nucleotide 5' of the PAM. For example, in the case of a 5'-NNNNNNNNNNNNNNNNNNNNNN NRG -3' (SEQ ID NO: 2), the target nucleic acid can be a sequence corresponding to N, wherein N can be any nucleotide, and the underlined NRG sequence (R is G or A) is the Streptococcus pyogenes PAM. In some embodiments, the PAM sequence used as a sequence recognized by SpCas9 in the compositions and methods of the present disclosure is NGG, wherein N can be A, T, C or G.

[0104] The percent complementarity between the spacer sequence and the target nucleic acid can be about less than, at least less than, at least about less than, at most less than, or at most about less than: 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments, the spacer sequence of the guide RNA and the target nucleic acid in the target gene are 100% complementary. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is 100% over the six consecutive 5' nucleotides of the target sequence of the complementary strand of the target nucleic acid. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is at least 60% over about 20 consecutive nucleotides. In other embodiments, the spacer sequence of the guide RNA and the target sequence in the target gene can contain up to 10 mismatches, such as up to 9, up to 8, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2, or up to 1 mismatch.

[0105] The LPA gRNA can target a target sequence within exon 3 of the LPA gene. In some embodiments, the LPA gRNA comprises a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NOs: 3-10 listed in Table 1. In some embodiments, the LPA gRNA comprises a spacer sequence selected from SEQ ID NOs: 18-25 listed in Table 1.

[0106]

[0107] In some embodiments, the gRNA comprises a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NO: 3-10, or a variant thereof. In some embodiments, the gRNA comprises a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NO: 3-10. In some embodiments, the gRNA comprises a spacer sequence having one, two, or three mismatches with an RNA sequence corresponding to any one of the target sequences listed in SEQ ID NO: 3-10. In some embodiments, the gRNA comprises a spacer sequence listed in SEQ ID NO: 18-25, or a variant thereof. In some embodiments, the gRNA comprises a spacer sequence selected from SEQ ID NO: 18-25. In some embodiments, the gRNA comprises a spacer sequence having one, two, or three mismatches with a sequence selected from SEQ ID NO: 18-25. In some embodiments, the gRNA is a sgRNA.

[0108] In some embodiments, two gRNAs comprising a spacer complementary to the target sequence of the LPA gene are provided to the cell. In some embodiments, the gRNA is any two gRNAs comprising a spacer corresponding to any one of the target sequences listed in SEQ ID NO: 3-10 or a variant thereof. In some embodiments, one or both of the two gRNAs comprise a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NO: 3-10. In some embodiments, one or both of the two gRNAs comprise a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NO: 3-10 with one, two or three mismatches. In some embodiments, one or both of the two gRNAs comprise a spacer sequence listed in SEQ ID NO: 18-25 or a variant thereof. In some embodiments, one or both of the two gRNAs comprise a spacer sequence selected from SEQ ID NO: 18-25. In some embodiments, one or both of the two gRNAs comprise a spacer sequence selected from SEQ ID NO: 18-25. In some embodiments, one or both of the two gRNAs comprise a spacer sequence with one, two or three mismatches with a sequence selected from SEQ ID NO: 18-25.

[0109] In some embodiments, the gRNA comprises a first gRNA comprising a spacer having a sequence of SEQ ID NO: 18 or a sequence having at least 85% (e.g., at least 90% or at least 95%) homology to SEQ ID NO: 18, and a second gRNA comprising a spacer having a sequence of any one of SEQ ID NOs: 19-25 or a sequence having at least 85% (e.g., at least 90% or at least 95%) homology to any one of SEQ ID NOs: 19-25. In some embodiments, the gRNA comprises a first gRNA comprising a spacer having a sequence of SEQ ID NO: 18 and a second gRNA comprising a spacer having a sequence of any one of SEQ ID NOs: 19-25.

[0110] In some embodiments, the gRNA comprises a spacer sequence set forth in SEQ ID NO: 18, or a sequence having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to SEQ ID NO: 18. In some embodiments, the gRNA comprises a spacer sequence having no more than 3 mismatches (e.g., 1 or 2 mismatches) relative to SEQ ID NO: 18. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 18.

[0111] In some embodiments, the LPA gRNA comprises a spacer sequence corresponding to any one of the target sequences listed in SEQ ID NOs: 12-17 listed in Table 2 below. In some embodiments, the LPA gRNA comprises a spacer sequence selected from SEQ ID NOs: 26-31 listed in Table 2.

[0112]

[0113] In some embodiments, gRNA is a chemically modified gRNA. Various types of RNA modifications can be introduced into gRNA to enhance stability, reduce the possibility or degree of innate immune response and / or enhance other properties described in the art. The gRNA described herein may include one or more modifications, including internucleoside bonds, purine or pyrimidine bases or sugars. In some embodiments, modifications are introduced at the ends of gRNA using chemical synthesis or polymerase. Modified nucleic acids and examples of their synthesis are disclosed in WO2013 / 052523. The synthesis of modified polynucleotides is also described in Verma and Eckstein, Annual Review of Biochemistry, Vol. 76, 99-134 (1998).

[0114] The chemically modified gRNA can include one or more thiophosphorylated 2'-O-methyl nucleotides at the 3' end and / or 5' end of the gRNA. In some embodiments, the chemically modified gRNA includes thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA. In some embodiments, the chemically modified gRNA includes thiophosphorylated 2'-O-methyl nucleotides at the 5' end of the gRNA. In some embodiments, the chemically modified gRNA includes three or four thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA and / or includes three or four thiophosphorylated 2'-O-methyl nucleotides at the 5' end. In some embodiments, SEQ ID NO: Any one of 18-25 and 26-31 can be chemically modified to have one, two, three or four thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA; One, two or three thiophosphorylated 2'-O-methyl nucleotides at the 5' end of the gRNA, or a combination thereof. The number and position of thiophosphate bonds can vary.In some embodiments, the bond can be between the first and second, second and third, third and fourth positions, fourth and fifth, fifth and sixth, sixth and seventh, seventh and eighth, eighth and ninth, ninth and tenth or other positions at the 5' end of gRNA.In some embodiments, the bond can be between the first and second, second and third, third and fourth positions, fourth and fifth, fifth and sixth, sixth and seventh, seventh and eighth, eighth and ninth, ninth and tenth or other positions at the 3' end of gRNA.In some embodiments, the chemically modified gRNA has the sequence of any one of the gRNA described herein (for example, SEQ ID NO: 32), and has one or more chemically modified nucleotides and / or one or more thiophosphate bonds described herein.As an example, the chemically modified gRNA is SEQID NO: 11.

[0115] In some embodiments, nucleotide analogs / modifications may include 2-amino-6-chloropurine riboside-5'-triphosphate, 2-aminopurine-riboside-5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-amino-2'-deoxycytidine-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-fluorothymidine-5'-triphosphate, 2'-O-methyl-inosine-5'-triphosphate , 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-iodo-uridine-5 '-triphosphate, 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxyuridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine riboside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate , 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-riboside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, puromycin-5'-triphosphate or xanthosine-5'-triphosphate. The base modified nucleotides may include 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate and pseudouridine-5'-triphosphate, pyridine-4-ketone ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine, 1-taurine methyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thiodihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine and 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine,pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5 -methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyl adenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wyosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine and N2,N2-dimethyl-6-thio- Guanosine, 5'-O-(1-phosphorothioate)-adenosine, 5'-O-(1-phosphorothioate)-cytidine, 5'-O-(1-phosphorothioate)-guanosine, 5'-O-(1-phosphorothioate)-uridine, 5'-O-(1-phosphorothioate)-pseudouridine, 6-aza-cytidine, 2-thio-cytidine, α-thio-cytidine, pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine, α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, pyrrolo-cytidine, inosine, α-thio-guanosine, 6-methyl-guanosine, 5-methyl-cytidine, 8-oxo-guanosine,7-deaza-guanosine, N1-methyl-adenosine, 2-amino-6-chloro-purine, N6-methyl-2-amino-purine, pseudo-iso-cytidine, 6-chloro-purine, N6-methyl-adenosine, α-thio-adenosine, 8-azido-adenosine or 7-deaza-adenosine.

[0116] At least one modified nucleotide and / or at least one nucleotide analog may include 1-methyladenosine, 2-methyladenosine, N6-methyladenosine, 2'-O-methyladenosine, 2-methylthio-N6-methyladenosine, N6-isopentenyladenosine, 2-methylthio-N6-isopentenyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, N6-hydroxynorvalylcarbamoyladenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyladenosine, inosine, 3-methylcytidine, 2-O-methylcytidine, 2-thiocytidine, N4-acetylcytidine, lysine, 1-methylguanosine, 7-methylguanosine, 2'-O-methylguanosine, braided glycoside, epoxy braided glycoside, 7-cyano-7-deazaguanosine, 7-aminomethyl-7-deazaguanosine, pseudouridine, dihydrouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, 4-thiouridine, 5-methyl-2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 5'-hydroxyuridine, 5-methoxyuridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-aminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethylaminomethyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine or 5-(isopentenylaminomethyl)-2'-O-methyluridine.

[0117] In some embodiments, the chemical modification includes pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, or 2'-O-methyluridine. In some embodiments, the modification comprises 2'-O-methyluridine (2'OMe-rU), 2-O-methylcytidine (2'OMe-rC), 2'-O-methyladenosine (2'OMe-rA), or 2'-O-methylguanosine (2'OMe-rG).

[0118] The gRNA can contain any number of modified nucleotides. For example, the percentage of modified nucleotides in the gRNA molecule can be below, can be at least below, can be about below, or can be at least about below 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, or 75%.

[0119] As an example, SEQ ID NO: 3 can be chemically modified to: * a * u * UAA UGA CAU ACG CAU UU" (T is converted to U), where u = 2'OMe-rU; a = 2'OMe-rA; g = 2'OMe-rG; * = thiolated phosphate. In some embodiments, the LPA gRNA comprises a chemically modified SEQ ID NO: 18, such as "g * a * u *UAA UGA CAU ACG CAUUU", where u = 2'OMe-rU; a = 2'OMe-rA; g=2'OMe-rG; * = thiolated phosphate.

[0120] In some embodiments, the gRNA comprises or consists of: GAUUAAUGACAUACGCAUUUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 32). One or more nucleotides of the gRNA (e.g., SEQ ID NO: 32) can be one or more modified nucleotides, for example, one or more U of the gRNA (e.g., SEQ ID NO: 32) can be 2'OMe-rU, one or more A of the gRNA (e.g., SEQ ID NO: 32) can be 2'OMe-rA, one or more C of the gRNA (e.g., SEQ ID NO: 32) can be 2'OMe-rC, and one or more G of the gRNA (e.g., SEQ ID NO: 32) can be 2'OMe-rG. One or more positions of the gRNA (e.g., SEQ ID NO: 32) can be modified, such as thiolated phosphates. In some embodiments, the gRNA comprises or consists of the following: Sequence of SEQ ID NO: 11: 5'- g * a * u * UAA UGA CLOSE ACG CLOSE UU G UUU UAG Agc uag aaa uag cAA GUU AAA AUA AGG CUAGUC CGU UAU Caa cuu gaa aaa gug gca ccg agu cgg ugc u * u * u * u-3', where u = 2'OMe-rU; a = 2'OMe-rA; c = 2'OMe-rC; g =2'OMe-rG; * = thiolated phosphate. The underlined sequence corresponds to the spacer region.

[0121] In some embodiments, more than one guide RNA can be used with the CRISPR / Cas nuclease system. Each guide RNA can contain different targeting sequences so that the CRISPR / Cas system cleaves more than one target nucleic acid. In some embodiments, one or more guide RNAs can have the same or different properties within the Cas9 RNP complex, such as activity or stability. When more than one guide RNA is used, each guide RNA can be encoded on the same or different vectors.

[0122] The gRNA described herein can be produced by in vitro transcription (IVT), synthesis and / or chemical synthesis methods or a combination thereof. Enzymatic (IVT), solid phase, liquid phase, combinatorial synthesis methods, small area synthesis and ligation methods are used. In one embodiment, the gRNA is prepared using an IVT enzymatic synthesis method. Methods for preparing polynucleotides by IVT are known in the art and are described in WO2013 / 151666. Polynucleotide constructs and vectors can be used to transcribe the gRNA described herein in vitro.

[0123] How to edit LPA The content provided herein includes a method for editing LPA by functionally knocking out or reducing the expression of LPA genes in the cell genome using genome editing. The method can be used to treat subjects with lipoprotein-related diseases or disorders, such as patients with cardiovascular disease. In some embodiments, the method includes administering to a subject (e.g., a primate subject) more than one nanoparticle complexed with (a) a guide RNA (gRNA) or a nucleic acid encoding a gRNA targeting an LPA gene and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby treating cardiovascular disease in primate subjects.

[0124] More than one nanoparticle can be applied to the subject twice or more, for example, twice, for treatment. Nanoparticles can be applied to the subject twice at intervals of a suitable time period, for example, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, one year, eighteen months, two years, three years, five years, ten years, fifteen years or longer. In some embodiments, two intervals of about two weeks to about two months, for example, about three weeks, are applied twice in two or more administrations. In some embodiments, each interval of about two weeks to about two months, for example, about three weeks, is applied twice in two or more administrations. The suitable time period between the two administrations can be the same or different from the suitable time period between the other two administrations. In some embodiments, the methods described herein include applying a single dose of more than one nanoparticle to the subject within the time period provided, for example, one year, two years, three years, five years, six years, eight years, ten years, fifteen years, twenty years or longer. In some embodiments, the methods described herein include applying a single dose of more than one nanoparticle to the subject throughout the life of the subject. In some embodiments, the methods described herein include applying a single dose of more than one nanoparticle to the subject. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.01-5 mg / kg, such as 0.05-2 mg / kg, 0.5-3 mg / kg, or 0.1-1 mg / kg gRNA per administration. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.01-5 mg / kg, such as 0.05-2 mg / kg, 0.5-3 mg / kg, or 0.1-1 mg / kg total nucleic acid (i.e., the sum of LPA gRNA and RNA encoding RNA-guided endonucleases (e.g., Cas9 mRNA) per administration.

[0125] In some embodiments, gRNA targets within or near the coding sequence in the LPA gene. In some embodiments, gRNA targets any one of the exons of the LPA gene. In some embodiments, gRNA targets sequences within exon 3 of the LPA gene. The gRNA may include a spacer sequence complementary to the target sequence within exon 3 of the LPA gene. In some embodiments, one or more spacers are complementary to sequences within or near exon 3 of the LPA gene (e.g., within any one of the following distances from exon 3: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more bases). The complementarity between the spacer of the gRNA and the target sequence in the LPA gene can be complete or incomplete. In some embodiments, complementarity can be at least 70%, 80%, 90%, 100% or a number or range between any two of these values. In some embodiments, complementarity is complete, ie, 100%.

[0126] In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 18-25, or a sequence having at least or about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to any one of SEQ ID NOs: 18-25. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 18-25, or a sequence having one, two, or three mismatches to any one of SEQ ID NOs: 18-25.

[0127] In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 11, or a sequence having about, at least, or at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% sequence homology to SEQ ID NO: 11. In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 11.

[0128] The gRNA used herein can enhance on-target activity while significantly reducing potential off-target effects (i.e., cleavage of genomic DNA at undesirable locations other than the LPA gene). In some embodiments, off-target binding is reduced by about less than, at least less than, or at least about less than: 80%, 85%, 90%, 95%, 98%, 99%, or 100%.

[0129] The RNA-guided endonuclease can be a Cas endonuclease described herein or known in the art. The Cas endonuclease can be naturally occurring or non-naturally occurring (e.g., recombinant or with mutations). In some embodiments, the Cas endonuclease is a Cas9 endonuclease or a variant thereof. In some embodiments, the DNA endonuclease is selected from the group consisting of: Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is a Cas9 endonuclease or a variant thereof. In some embodiments, the Cas9 endonuclease is from Streptococcus pyogenes (SpyCas9). In some embodiments, the Cas9 endonuclease is from Staphylococcus lugdunensis (SluCas9).

[0130] In some embodiments, genetic modification of the LPA gene results in a significant reduction in blood or plasma Lp(a) levels in a subject (e.g., a mammal, NHP, or human subject). In some embodiments, plasma Lp(a) levels are reduced by 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125 0%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values. In some embodiments, the reduction in plasma Lp(a) levels is about less than, at least less than, or at least about less than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, 100%, or a number or range between any two of these values.

[0131] In some embodiments, the plasma Lp(a) level in a genetically modified subject (e.g., a mammal, NHP, human subject) is about less than, less than, or less than about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 119%, 120%, 121%, 122%, 123%, 124%, 125 3%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.

[0132] In some embodiments, the reduction is relative to the LPA expression or concentration of LPA protein in the plasma of a subject (e.g., a mammal, NHP, a human subject) before administering more than one nanoparticle. In some embodiments, the reduction is relative to the LPA expression or concentration of LPA protein in one or more untreated subjects. In some embodiments, the reduction is relative to a reference level of the concentration of LPA expression or LPA protein in a healthy and / or unmodified subject.

[0133] In some embodiments, the plasma Lp(a) level after implementation of the method is reduced to about 50 mg / dL or less (e.g., about less than, at most less than, or at most about less than: 40 mg / dL, 30 mg / dL, 20 mg / dL or less). In some embodiments, the plasma Lp(a) level after implementation of the method is reduced to about 40 mg / dL or less. In some embodiments, the plasma Lp(a) level after implementation of the method is reduced to about 30 mg / dL or less. In some embodiments, the plasma Lp(a) level after implementation of the method is reduced to about 20 mg / dL or less.

[0134] Pharmaceutical compositions and therapeutic applications Contents provided herein also include pharmaceutical compositions for implementing the methods disclosed herein. Compositions may include one or more gRNAs described herein, RNA-guided endonucleases, or nucleotide sequences encoding RNA-guided endonucleases. In some embodiments, compositions may also include polynucleotides to be inserted (e.g., donor templates) to achieve the desired genetic modification methods disclosed herein.

[0135] In some embodiments, one or more gRNAs each comprise a spacer region complementary to a genomic sequence within or near exon 3 of an LPA gene (e.g., within any of the following distances from exon 3 of an LPA gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more bases). The gRNA may comprise a spacer region sequence complementary to a target sequence within exon 3 of an LPA gene. In some embodiments, the gRNA used in the methods herein comprises a spacer region sequence of any one of SEQ ID NOs: 18-25. In some embodiments, the gRNA comprises a spacer region sequence of SEQ ID NO: 18 or a sequence having at least 85% homology to a sequence of SEQ ID NO: 18. In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 11 or a sequence having at least 85% homology to the sequence of SEQ ID NO: 11.

[0136] In some embodiments, the RNA-guided endonuclease is selected from Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonucleases or functional derivatives thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 endonuclease is from Streptococcus pyogenes (SpyCas9). In some embodiments, the Cas9 endonuclease is from Staphylococcus lugdunensis (SluCas9). In some embodiments, the DNA sequence transcribed into the nucleic acid encoding the DNA endonuclease is codon optimized. In some embodiments, the nucleic acid encoding the DNA endonuclease includes a 5' cap structure and a 3' poly (A) tail. In some embodiments, the nucleic acid encoding the DNA endonuclease is connected to the gRNA via a covalent bond.

[0137] In some embodiments, one or more of the nucleic acid sequences and / or polypeptides can be delivered to cells in vitro or in vivo via a viral or non-viral based delivery system, including adenoviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, lentiviral vectors, herpes virus vectors, nanoparticles, liposomes, lipid nanoparticles, poxviruses, naked DNA administration, plasmids, cosmids, bacteriophages, encapsulated cell technology, and the like.

[0138] In some embodiments, the compounds of the compositions disclosed herein (e.g., LPA gRNA and nucleic acids encoding RNA-guided endonucleases) can be formulated in liposomes or lipid nanoparticles. In some embodiments, the compounds of the compositions are formulated in lipid nanoparticles (LNPs). The term "lipid nanoparticle" refers to a nanoscale particle composed of lipids having a size measured in nanometers (e.g., 1-5,000 nm). In some embodiments, the lipids contained in the lipid nanoparticles include cationic lipids and / or ionizable lipids. Any suitable cationic lipids and / or ionizable lipids known in the art can be used to prepare LNPs for delivery of gRNA and Cas endonucleases to cells. Exemplary cationic lipids include one or more positively charged amine groups. In some embodiments, cationic lipids are ionizable so that they can exist in positively charged or neutral forms according to pH. In some embodiments, the cationic lipids of lipid nanoparticles are included in protonatable tertiary amine head groups that display positive charges at low pH. Lipid nanoparticles may also comprise one or more of neutral lipids, charged lipids, steroids, and polymer-conjugated lipids.

[0139] In some embodiments, the lipid nanoparticles may have an average diameter of about 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, or a number or range between any two of these values. In some embodiments, the lipid nanoparticle size is about 50 to about 100 nm in diameter, or about 70 to about 90 nm in diameter, or about 55 to about 95 nm in diameter. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.1-5 mg / kg (determined by the total nucleic acid (e.g., the sum of LPA gRNA and Cas9 mRNA) per administration, including 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, 2 mg / kg, 2.1 mg / kg, 2.2 mg / kg, 2.3 mg / kg, 2.4 mg / kg, 2.5 mg / kg, 2.6 mg / kg, 2.7 mg / kg, 2.8 mg / kg, 2.9 In some embodiments, more than one nanoparticle is administered to a subject at or about a dose of 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, or 3.0 mg / kg (in some embodiments, determined by the sum of LPA gRNA and SpCas9 mRNA).

[0140] In some embodiments, the compound of the composition described herein is encapsulated in the lipid portion of the lipid nanoparticle or in the aqueous space encapsulated by some or all of the lipid portion of the lipid nanoparticle. Encapsulation can be complete encapsulation, partial encapsulation, or both. In some embodiments, the nucleic acid and / or polypeptide is completely encapsulated in the lipid nanoparticle.

[0141] In some embodiments, one or more compounds described herein are associated with liposomes or lipid nanoparticles via covalent or non-covalent bonds. In some embodiments, any compound in the composition may be contained in a liposome or lipid nanoparticle, either alone or together.

[0142] In some embodiments, the composition described above may also have one or more additional reagents, wherein such additional reagents are selected from a buffer, a buffer for introducing a polypeptide or polynucleotide into a cell, a washing buffer, a control reagent, a control vector, a control RNA polynucleotide, a reagent for producing a polypeptide from DNA in vitro, an adapter for sequencing, etc. The buffer may be a stabilization buffer, a reconstitution buffer, a dilution buffer, etc. In some embodiments, the composition may also include one or more components that can be used to promote or enhance the target binding or cleavage of the endonuclease to the DNA or improve the specificity of the targeting.

[0143] In some embodiments, any component of the composition is formulated with a pharmaceutically acceptable excipient such as a carrier, solvent, stabilizer, adjuvant, diluent, etc., depending on the specific mode of administration and dosage form. In embodiments, the guide RNA composition is generally formulated to achieve a physiologically compatible pH, and ranges from about pH 3 to about pH 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In some embodiments, the pH is adjusted to a range of about pH 5.0 to about pH 8.

[0144] Suitable excipients can include, for example, carrier molecules including large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, and inactive viral particles. Other exemplary excipients include antioxidants (such as, but not limited to, ascorbic acid), chelating agents (such as, but not limited to, EDTA), carbohydrates (such as, but not limited to, dextrins, hydroxyalkyl cellulose, and hydroxyalkyl methyl cellulose), stearic acid, liquids (such as, but not limited to, oils, water, saline, glycerol, and ethanol), wetting agents or emulsifiers, pH buffer substances, and the like.

[0145] Physiologically tolerable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that do not contain any substance except the active ingredient and water, or contain buffers such as sodium phosphate, saline or both at physiological pH, such as phosphate buffered saline. Aqueous carriers can contain more than one buffer salt, as well as salts (such as sodium chloride and potassium chloride), dextrose, polyethylene glycol and other solutes. Liquid compositions can also contain a liquid phase in addition to water and a liquid phase without water. Examples of such additional liquid phases are glycerol, vegetable oils such as cottonseed oil and water-oil emulsions. The amount of active compound used in a cell composition that is effective in treating a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.

[0146] In some embodiments, the compound described herein of the composition (e.g., RNA-guided endonucleases or nucleic acids encoding RNA-guided endonucleases and / or gRNA) can be delivered via transfection, such as calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, electronuclear transport, chemical transduction, electrotransduction, Lipofectamine-mediated transfection, Effectene-mediated transfection, lipid nanoparticle (LNP)-mediated transfection, or any combination thereof. In some embodiments, lipid nanoparticles are used to introduce the composition into cells via lipid-mediated transfection.

[0147] The compositions described herein can be administered to subjects in need to treat cardiovascular disease or reduce the risk of developing cardiovascular disease. Therefore, the present disclosure also provides a gene therapy method for treating cardiovascular disease in patients or reducing the risk of developing cardiovascular disease in subjects by editing the LPA gene of the subject. In some embodiments, the gene therapy method functionally knocks out the LPA gene in the genome of the relevant cell type in the patient. The LPA gene of the relevant cells (e.g., hepatocytes) in the subject is edited using the materials and methods described herein, which use RNA-guided endonucleases (such as Cas9) to permanently delete, insert, edit, correct or replace the target sequence or insert an exogenous sequence from the genome, thereby functionally knocking out the LPA gene. This can provide a permanent cure for cardiovascular disease by permanently reducing the Lp (a) level in the blood.

[0148] In some embodiments, a method for treating cardiovascular disease or disorder in a subject (e.g., a primate subject) in need thereof is disclosed. The method may include administering to a primate subject more than one nanoparticle complexed with (a) a guide RNA (gRNA) or a nucleic acid encoding a gRNA targeting an LPA gene and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby alleviating cardiovascular disease or disorder in a primate subject. More than one nanoparticle may be administered to a subject twice or more, for example, twice, for treatment. Two administrations of nanoparticles to a subject may be spaced apart by a suitable time period. In some embodiments, a suitable time period is or is about: one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, one year, two years, three years or longer. In some embodiments, two of the two or more administrations are spaced apart by about two weeks to about two months, for example, about three weeks. In some embodiments, each of the two or more administrations is spaced apart by about two weeks to about two months, for example, about three weeks. In some embodiments, twice or more times are used for two intervals of about one month to about four months, for example, about two months or three months, or longer. In some embodiments, twice or more times are used for every two intervals of about one month to about four months, for example, about two months or three months. In some embodiments, twice or more times are used for two intervals of at least two months or three months. In some embodiments, twice or more times are used for every two intervals of at least two months or three months. In some embodiments, the Lp (a) level in the subject receiving the single application of compositions described herein can be significantly reduced (for example, reduced by at least 20%, 30%, 40%, 50%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher), and after use, remain on the reduced level for at least two months, three months, four months, six months, ten months, one year, eighteen months, two years, three years, four years, five years, ten years, fifteen years, twenty years or longer. The suitable time period between two applications can be the same or different with the suitable time period between another two applications. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.1-5 mg / kg of total RNA (e.g., LPA gRNA and Cas9 mRNA), e.g., 0.5-3 mg / kg of total RNA per administration. In some embodiments, LPA gRNA or a nucleic acid encoding LPA gRNA is administered to a subject at a dose of or about 0.1-5 mg / kg, e.g., 0.1 mg / kg to 5 mg / kg gRNA per administration.In some embodiments, the nucleic acid encoding the RNA-guided endonuclease is administered to the subject at a dose of or about the following per administration: 0.1-5 mg / kg gRNA, such as 0.5-3 mg / kg gRNA. For each administration to the subject, the dose may be the same or different. In some embodiments, more than one nanoparticle is administered to the subject at a dose of about 0.02 to about 1 mg / mL of total RNA (e.g., the sum of LPA gRNA and Cas9 mRNA), such as about 0.1 to 0.6 mg / mL of total RNA per administration. In some embodiments, the methods disclosed herein include administering more than one nanoparticle to the subject in a single administration. For example, more than one nanoparticle can be administered to the subject in a single administration of about 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg or 3.0 mg / kg RNA content (a) LPA gRNA or nucleic acid encoding LPA gRNA and (b) nucleic acid encoding RNA-guided endonuclease. As described herein, a single administration treatment can be effective for the subject, and thus the subject does not require any additional subsequent treatment. For example, in some embodiments, the subject receives a single administration of more than one nanoparticle within a period of three months, four months, five months, six months, one year, two years, three years, four years, five years, six years, seven years, eight years, nine years, ten years, fifteen years, twenty years, twenty-five years, thirty years, thirty-five years, forty years, fifty years, sixty years or more, or a number or range between any two of these values.

[0149] In some embodiments, the target tissue for the compositions and methods described herein is liver tissue. In some embodiments, the target cell for the compositions and methods described herein is a hepatocyte.

[0150] In some embodiments, the pharmaceutical composition can be administered by aerosol delivery, nasal delivery, vaginal delivery, rectal delivery, buccal delivery, ocular delivery, topical delivery, surface delivery, intracisternal delivery, intraperitoneal delivery, oral delivery, intramuscular injection, intravenous injection, subcutaneous injection, intranodal injection, intratumoral injection, intraperitoneal injection and / or intradermal injection or any combination thereof. Administration can be local or systemic. Systemic administration includes enteral and parenteral administration. In some embodiments, more than one administration can be used to achieve the desired gene expression level within a time period of various intervals (e.g., daily, weekly, monthly or annually).

[0151] The pharmaceutical composition can be administered to a subject in need thereof in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means the amount of the pharmaceutical composition that will cause the desired therapeutic effect and / or biological or medical response of a tissue, system, animal or human. Administration can result in a desired decrease in LPA gene expression, such as a desired decrease in plasma levels of Lp(a).

[0152] As used herein, the term "cardiovascular disease" refers to disorders of the heart and blood vessels, and includes disorders of arteries, veins, arterioles, venules, and capillaries. In some embodiments, the cardiovascular disease is stroke, myocardial infarction, atherosclerosis, familial hypercholesterolemia, atherosclerosis, thrombosis, calcific aortic valve disease, coronary artery disease, peripheral arterial disease, cerebrovascular disease, renal artery stenosis, aortic aneurysm, cardiomyopathy, hypertensive heart disease, heart failure, cor pulmonale, congenital heart disease, or rheumatic heart disease. In some embodiments, the methods and compositions described herein can be used to treat calcific aortic valve disease, myocardial infarction, coronary heart disease, atherosclerosis, thrombosis, stroke, or a combination thereof.

[0153] In some embodiments, the subject has one or more of the cardiovascular disorder symptoms affecting the heart, brain, one or both legs, pelvis, one or both arms and / or shoulders. Symptoms of cardiovascular disorders affecting the heart include, but are not limited to, chest pain, chest discomfort, pain in one or both arms, one or both shoulders, neck, jaw or back, shortness of breath, dizziness, rapid heartbeat, nausea, abnormal heartbeat, fatigue and / or myocardial infarction. Symptoms of cardiovascular disorders affecting the brain include, but are not limited to, sudden numbness or weakness of the face, one or both arms or one or both legs, sudden confusion or language or difficulty understanding speech, sudden difficulty seeing in one or both eyes, sudden dizziness, difficulty walking or loss of balance or coordination and / or sudden severe headache without known cause. Symptoms of cardiovascular disease affecting one or both legs, pelvis, one or both arms and / or shoulders include, but are not limited to, muscle pain, muscle cramps, cold sensation of one or both feet and / or toes, one or both hands and / or fingers and / or numbness or weakness of one or both feet and / or toes, one or both hands and / or fingers.

[0154] In some embodiments, a subject in need of treatment can have abnormal levels (higher or lower than levels in healthy individuals) of total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, complete blood count with differential, Lp(a), apolipoprotein B, homocysteine, hemoglobin A1c, fasting glucose, insulin, creatine kinase, alanine aminotransferase, aspartate aminotransferase, fibrinogen, thyroid stimulating hormone, ultra-sensitive C-reactive protein, urine albumin-to-creatinine ratio, MPO, vitamin D, trimethylamine N-oxide, amino terminal, pro-brain natriuretic peptide, serum creatinine, global risk score, or a combination thereof.

[0155] In some embodiments, the subject may have been pretreated with a steroid and / or antihistamine. For example, the subject may have been pretreated with dexamethasone, famotidine, diphenhydramine, or a combination thereof. Pretreatment can be performed for about less than, at least less than, at least about less than, at most less than, or at most about less than: 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, 1 day, 2 days, 5 days, 10 days prior to administration.

[0156] In some embodiments, the method further comprises identifying a subject in need of treatment. In some embodiments, the method further comprises measuring the blood level of Lp(a) in the primate subject before, during and / or after administration.

[0157] In some embodiments, the subject has a high level of Lp(a) (e.g., plasma Lp(a)) prior to administration. Subjects with high levels of Lp(a) can include, for example, subjects with Lp(a) levels greater than 90% of the human population. In some embodiments, the subject has symptoms of cardiovascular disease. In some embodiments, the subject does not have symptoms of cardiovascular disease. In some embodiments, the subject is at risk of developing cardiovascular disease. In some embodiments, the subject is suspected of having or developing cardiovascular disease.

[0158] In some embodiments, the subject has a plasma Lp(a) level of greater than about 30 mg / dL prior to administration (such as greater than about any of 40 mg / dL, 50 mg / dL, 60 mg / dL, 70 mg / dL, 80 mg / dL, 100 mg / dL, 125 mg / dL, 150 mg / dL, 175 mg / dL, 200 mg / dL, 225 mg / dL, 250 mg / dL, 275 mg / dL, 300 mg / dL or greater). In some embodiments, the subject in need of treatment has a plasma Lp(a) level greater than 50 mg / dL. In some embodiments, the subject has a plasma Lp(a) level of greater than about 30 mg / dL prior to administration (such as greater than about any of 100 nmol / L, 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 350 nmol / L, 400 nmol / L or greater). In some embodiments, the subject has one or more genetic markers (e.g., deletions, insertions, and / or mutations) in an endogenous LPA gene or its regulatory sequence such that the activity (including expression level or function) of the apo(a) protein is significantly increased compared to a normal healthy subject.

[0159] In some embodiments, the subject in need of treatment is a patient with high levels of Lp(a) (as defined as Lp(a) levels above 90% of the population (e.g., above 60 mg / dL)) and symptoms of a lipoprotein-related disease (e.g., cardiovascular disease). In some embodiments, the subject may be a human suspected of having a lipoprotein-related disease. Alternatively, the subject may be a human diagnosed as having a risk of a lipoprotein-related disease due to the presence of an Lp(a) level of more than 60 mg / dL or 70 mg / dL or 80 mg / dL or 100 mg / dL or 200 mg / dL or 300 mg / dL. In some embodiments, the subject in need of treatment may have an LPA gene variant associated with an increased risk of a lipoprotein-related disease and / or increased Lp(a) expression. In some embodiments, the subject is a mammal. In some embodiments, the subject is a primate. In some embodiments, the subject is a human.

[0160] The methods and compositions described herein can reduce plasma low-density lipoprotein (LDL) levels, such as plasma Lp(a) levels, thereby reducing the risk of cardiovascular disease, such as the risk of heart attack, stroke, blood clots, fat accumulation in the veins and other coronary artery disease, the likelihood of death associated with cardiovascular events, or a combination thereof. In some embodiments, the methods and compositions described herein can reduce or alleviate one or more symptoms of cardiovascular disease.

[0161] In some embodiments, after implementing the method, the plasma Lp(a) level in the subject is reduced to about 50 mg / dL or less (e.g., about less than, at most less than, or at most about less than: 40 mg / dL, 30 mg / dL, 20 mg / dL or less). In some embodiments, after implementing the method, the plasma Lp(a) level in the subject is reduced to about 40 mg / dL or less. In some embodiments, after implementing the method, the plasma Lp(a) level in the subject is reduced to about 30 mg / dL or less. In some embodiments, after implementing the method, the plasma Lp(a) level in the subject is reduced to about 20 mg / dL or less.

[0162] In some embodiments, after implementation of the method, plasma Lp(a) levels in the subject are reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or a number or range between any two of these values.

[0163] In some embodiments, after implementation of the method, the plasma LDL level in the subject is reduced by about less than, at least less than, or at least about less than: 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or a number or range between any two of these values.

[0164] The content provided herein also includes a kit for implementing the method described herein. The kit may include a nucleic acid targeting a genome (e.g., a gRNA targeting an LPA gene) and an RNA-guided endonuclease (e.g., Cas9) or a nucleic acid encoding an RNA-guided endonuclease. In any of the above kits, the kit may also include a polynucleotide (e.g., a donor template) to be inserted to achieve the desired genetic modification. The components of the kit may be in a separate container, or combined in a single container.

[0165] Any of the kits described above may also include one or more additional reagents selected from the following: a buffer, a buffer for introducing a polypeptide or polynucleotide into a cell, a wash buffer, a control reagent, a control vector, a control RNA polynucleotide, a reagent for producing a polypeptide from DNA in vitro, an adapter for sequencing, etc. The buffer may be a stabilization buffer, a reconstitution buffer, a dilution buffer, etc. The kit may also include one or more components that can be used to promote or enhance the target binding or cleavage of the endonuclease to the DNA or improve the specificity of the targeting.

[0166] In some embodiments, the test kit may also include instructions for use of the components of the test kit to implement the method described herein. The instructions for use of the implementation method are usually recorded on a suitable recording medium. For example, instructions for use can be printed on a substrate, such as paper or plastic, etc. Instructions for use can be present in the test kit as a packaging insert, in the label of the container of the test kit or its components (that is, associated with packaging or sub-packaging), etc. Instructions for use can exist as an electronic storage data file present in a suitable computer-readable storage medium (such as CD-ROM, floppy disk, flash drive, etc.). In some cases, there are no actual instructions for use in the test kit, but the means for obtaining instructions for use from a remote resource (for example, via the Internet) can be provided. The example of this embodiment is a test kit including a website, and instructions for use can be viewed at the website and / or instructions for use can be downloaded from the website. Like instructions for use, this means for obtaining instructions for use can be recorded on a suitable substrate.

[0167] Example Certain aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not intended to limit the scope of the disclosure in any way.

[0168] Example 1 In vitro validation of gRNA spacers targeting LPA The ability of gRNA to affect targeted cleavage is evaluated. The spacer sequences described in Table 1 herein are synthesized by in vitro transcription (IVT gRNA) and evaluated in a system using a human embryonic kidney (HEK) cell line engineered to constitutively express SpCas9 nuclease. The cleavage efficiency at the target site of each gRNA is measured using the TIDES protocol (Brinkman, EK et al. (2014). Nucleic Acids Research, 42(22): e168), wherein genomic DNA is amplified from treated cells using PCR primers flanking the predicted cleavage site, and the PCR product is subsequently subjected to Sanger sequencing. When double-strand breaks are generated in the genome of the cell, the cell attempts to repair the double-strand breaks. The repair process is prone to error, which can lead to the deletion or insertion of nucleotides at the double-strand break site. Because the fully repaired breaks are re-cleaved by the Cas9 nuclease, and the insertion or deletion of nucleotides will prevent Cas9 from cleaving, there will be an accumulation of insertions and deletions representing the cutting efficiency. The sequencing chromatogram data is then analyzed using a computer algorithm that calculates the frequency of inserting or deleting bases at the predicted cleavage site. The frequency of inserted or deleted bases (Indels (INDELs)) was used to calculate the overall cleavage frequency. However, due to the repetitive nature of some kringle IV regions, PCR amplification was not possible. For these guide RNA targets, indels could not be determined using this method. Results from IVT gRNA experiments in HEK cells are shown in Table 3, where the gRNAs are ranked according to their observed cleavage efficiency. In Table 3, Y = 100% matches the cynomolgus monkey (Macaca fascicularis).

[0169]

[0170] Example 2 Evaluation of LPA gene editing efficiency in non-human primates (NHPs) This example evaluates LPA gene editing efficiency in NHPs by measuring plasma Lp(a) levels before and after treatment.

[0171] NHPs were prescreened for SNPs in the LPA gene and Lp(a) plasma basal levels were measured. T4 gRNA (SEQ ID NO: 3) was selected to match the LPA gene of NHPs. Cas9 mRNA and T4 gRNA molecules were delivered to NHPs using a lipid nanoparticle (LNP) delivery vehicle. Figure 2In the study design shown in , LNPs encapsulating gRNA molecules and Cas9 mRNA were injected into NHPs. Specifically, each NHP was injected with 2 doses of RNA097 Cas9 mRNA (pseudouridine modified) and T4 gRNA (Group 4) encapsulated in Gen3 LNPs or 1 dose of RNA010 Cas9 mRNA (N-methylpseudouridine modified) and T4 gRNA (Group 5) encapsulated in Gen3 LNPs. Plasma samples were collected before and after treatment and plasma Lp (a) levels were monitored. The concentration of Lp (a) protein in the collected plasma was detected using a sandwich enzyme-linked immunosorbent assay (ELISA). Effective editing was observed, including about 50% liver editing at a dose of 2 mg / kg.

[0172] Figure 3A-3B The fourth group of NHP ( Figure 3A ) and group 5 NHP ( Figure 3B ) of plasma Lp(a) levels. Figure 4A-4B The fourth group of NHP ( Figure 4A ) and group 5 NHP ( Figure 4B ) of plasma Lp(a) in the presence or absence of leukemia / lymphocytes.

[0173] Results showed that the use of T4 gRNA and Cas9 mRNA significantly reduced NHP plasma Lp(a) levels. Reductions from baseline of 66% and 87% were observed in Group 4, and 75% and 86% were observed in Group 5.

[0174] Example 3 Toxicity studies of LPA gRNA preparations In this embodiment, toxicity studies were performed in NHP. The lipid nanoparticles encapsulating SEQ ID NO: 3 gRNA molecules (T4gRNA) and Cas9 mRNA were formulated as LPA gRNA preparations, referred to as "CTX320". The CTX320 preparations were administered to three groups of NHP (eg, cynomolgus monkeys) in a single dose at dosage levels of 0.5 mg / kg, 1.5 mg / kg, and 3.0 mg / kg, respectively. Plasma Lp (a) protein levels were measured using Mercodia ELISA assays. Figure 5 A non-limiting exemplary experimental design is depicted.

[0175] Figure 6 is a graph showing baseline Lp(a) levels in NHP plasma 14 days prior to treatment (Day -14).Baseline values ​​differed between individual NHPs due to the number of Kringle IV-2 repeats.

[0176] Figure 7 A non-limiting exemplary NHP study design is depicted. Plasma Lp(a) protein levels were measured 7 days prior to treatment and 8, 15, and 29 days after treatment.

[0177] Fig. 8A is a graph showing the percent change from baseline in plasma Lp(a) protein levels of NHPs following treatment with three different doses of CTX320: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg, compared to the control group. Figure 8B is a graph showing the percent change from baseline in serum Lp(a) protein levels of NHPs after treatment with three different doses of CTX320 compared to a control group: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg. The data show a dose-dependent decrease in plasma and serum Lp(a) protein after CTX320 administration. An approximately 66% decrease in Lp(a) protein from baseline was observed in NHPs treated with 1.5 mg / kg CTX320, and an approximately 92% decrease in Lp(a) protein was observed in NHPs treated with 3.0 mg / kg CTX320. No significant decrease in plasma Lp(a) protein was observed with 0.5 mg / kg CTX320 administration.

[0178] Figure 9A-9C is a graph showing plasma Lp(a) protein levels in NHPs before and after treatment with three different doses of CTX320: 0.5 mg / kg ( Fig. 9A )、1.5 mg / kg ( Fig. 9B ) and 3.0 mg / kg ( Fig. 9C ). Fig.9D Shown are the percent changes from baseline in plasma Lp(a) levels of NHPs following CTX320 treatment on day 29. An average 50% reduction or more in plasma Lp(a) levels from baseline was observed in NHPs treated with 1.5 mg / kg and 3 mg / kg CTX320 formulations.

[0179] After CTX320 treatment, serum tests were also performed on NHPs, including liver function tests, plasma lipid levels (e.g., triglycerides, HDL, LDL, and total cholesterol), renal function tests (e.g., blood urea nitrogen, creatinine, glucose, and calcium), markers of injury (e.g., lactate dehydrogenase (LDH), gamma glutamyl transferase, and c-reactive protein (CRP)), leukocytes, electrolyte panels, erythrocyte indices, coagulation profiles, and urine tests. Data (not shown) show that transient dose-dependent increases in liver enzymes and total bilirubin peaked at approximately 2-4 days after treatment and returned to baseline by day 15. The transient rise in LDH and CRP peaked at day 2 and returned to baseline by day 7. After CTX320 treatment, the weight of NHPs also remained stable. The data also showed that the 3 mg / kg CTX320 formulation did not alter cholesterol levels and induced a transient increase in triglyceride and LDL levels that peaked on days 2-4 after treatment, and a sharp decrease in HDL levels on day 4 after treatment. In addition, treatment with CTX320 was found to not alter the function of renal markers, including blood urea nitrogen and creatinine.

[0180] Example 4 Efficacy evaluation and toxicity study of LPA gRNA preparations This example reports another non-limiting exemplary efficacy and toxicity evaluation of the CTX320 formulation of Example 3.

[0181] according to Figure 5 In an experimental design, CTX320 formulations were administered to three groups of NHPs (e.g., cynomolgus monkeys) at dose levels of 0.5 mg / kg, 1.5 mg / kg, and 3.0 mg / kg in a single dose. Throughout the study, plasma Lp(a) protein levels were measured using Mercodia ELISA assays. Animals were sacrificed on day 85 after treatment.

[0182] Fig. 10A is a graph showing the percent change from baseline in serum Lp(a) protein levels of NHPs following treatment with three different doses of CTX320: 0.5 mg / kg, 1.5 mg / kg, and 3 mg / kg, compared to a control group. The data show a dose-dependent decrease in plasma and serum Lp(a) protein following CTX320 administration. An approximately 78% decrease from baseline in Lp(a) protein was observed in NHPs treated with 1.5 mg / kg CTX320, and an approximately 90% decrease in Lp(a) protein was observed in NHPs treated with 3.0 mg / kg CTX320. An approximately 19% decrease in plasma Lp(a) protein was observed with administration of 0.5 mg / kg CTX320. As Fig. 10AAs shown in , a single dose of CTX320 resulted in a sustained reduction in Lp(a), and the significant reduction in Lp(a) levels was sustained for the duration of the study at both the mid and high doses.

[0183] Fig. 10B The percentage change from baseline in plasma Lp(a) levels of NHPs after approximately 3 months of CTX320 treatment is shown. A significant reduction in Lp(a) levels from baseline was observed in NHPs treated with 1.5 mg / kg and 3 mg / kg CTX320 formulations. The results show that a single dose of CTX320 can lead to a sustained reduction in Lp(a) from baseline even after 3 months of treatment with moderate and high doses.

[0184] Fig.11 It is a graph showing the percentage of LPA gene editing in the liver and other organ tissues (including spleen, adrenal glands, brain, kidney, lung, epididymis, testis and ovary). The results show that the liver is the main organ for LPA gene editing, and after about 3 months of CTX320 treatment, only about 0.1%-5% of LPA gene editing was observed in the spleen. In addition, dose-dependent editing was also observed in the liver 85 days after treatment. About 40% LPA and 65% gene editing were observed after treatment with 1.5 mg / kg CTX320 and 3 mg / kg CTX320, respectively. Some results of LPA target editing in tissues are shown in Table 4.

[0185] Table 4: 3-month data (% indel) of LPA on-target editing in tissues

[0186] Additional data ( Figure 12A-12C ) also showed dose-dependent editing in reproductive tissues of the testis, epididymis, and ovary, with editing less than 0.5% 85 days after treatment with 3 mg / kg CTX320, and even lower editing after treatment with 0.5 mg / kg and 1.5 mg / kg CTX320.

[0187] Figure 13A-13B is a graph showing plasma levels of LNP component A after treatment. Figure 14A-14B is a graph showing the plasma levels of LNP component B after treatment. Toxicokinetic analysis showed that most of LNP components A and B were cleared from plasma one week after treatment with CTX320. Both LNP components A and B were excreted before 168 hours after injection.

[0188] Data (not shown) indicate that CTX320 causes a transient dose-dependent increase in liver function tests (eg, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin). No liver function impairment or damage was detected after treatment (eg, 85 days after administration).

[0189] Additional endpoint analyses, including body weight, clinical signs (e.g., aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin), urinalysis, hematology and coagulation, electrocardiogram, and histopathology (both gross and microscopic evaluations), revealed no CTX320-related changes throughout the duration of the study.

[0190] Example 5 Phase 1 Study Design A non-limiting exemplary design for a Phase 1 safety and tolerability clinical study of one or more of the LPA gene editing nanoparticles described herein (e.g., CTX320) is shown in Fig.15 middle.

[0191] In some cases, the Phase 1 clinical study of CTX320 is conducted in patients with elevated Lp(a) levels. For example, patients may have Lp(a) of ≥50 mg / dL or ≥100 nmol / L, with an increased risk of myocardial infarction (MI), regardless of established CVD risk factors. In some cases, patients may have Lp(a) of ≥50 mg / dL or ≥125 nmol / L. In some cases, patients may have Lp(a) levels of>180 mg / dL (>430 nmol / L), with an increased lifetime risk of atherosclerotic cardiovascular disease (ASCVD). Patient age may be between 18 and 75 years old. In some cases, HBA1C is tested approximately every 3 months in patients.

[0192] In some cases, subjects with advanced liver disease were excluded from the study. Advanced liver disease may include: (a) aspartate aminotransferase (AST), alanine aminotransferase (ALT) >3 × upper limit of normal (ULN) or direct bilirubin value >2 × ULN, and / or (b) baseline prothrombin time (international normalized ratio [INR]) >1.5 × ULN, and / or (c) Fibroscan or MRE reading ≥7.5 kPa, and / or (d) history of cirrhosis, and / or (e) history of alcohol or drug abuse, and / or (f) acute monitoring of ALT, AST, GGT, Bili., Alk. Phos., Albumin, INR, PT, and PTT to D30. Monitoring will continue until the end of the study (12 months).

[0193] Example 6 Persistence studies of LPA gRNA preparations This example reports a non-limiting exemplary persistence test study of the CTX320 formulation of Example 3. Specifically, this example uses ELISA to evaluate the persistence of LPA protein knockdown in plasma and evaluates LPA destruction in liver tissue. The persistence study also evaluated whether steroid and / or antihistamine pretreatment reduced liver function test elevations. Table 5 shows the persistence study design used in this example.

[0194]

[0195] Selected patients have elevated LP(a) levels greater than 100 mg / dL. Patients may be pretreated with steroids and / or antihistamines. For example, patients may be pretreated with 1 mg / kg dexamethasone, 0.5 mg / kg famotidine, and 5 mg / kg diphenhydramine one day prior to LNP administration, and then pretreated again 30-60 min prior to LNP administration.

[0196] Fig.16 is a graph showing the percent change from baseline in serum Lp(a) protein levels in patients following CTX320 treatment. At 56 days after administration, at least a 90% reduction from baseline in Lp(a) protein was still observed in patients treated with CTX320.

[0197] Serum tests including liver function tests (LFTs) and plasma lipid levels (e.g., triglycerides, HDL, LDL, and total cholesterol) were also performed on patients after CTX320 treatment.

[0198] Fig.17 Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin levels were compared in patients with pretreatment and 2.0 mg / kg CTX320 formulations and in patients without pretreatment and with 1.5 mg / kg and 3 mg / kg CTX320 formulations. The data showed that pretreatment with CTX320 formulation induced LFT elevations similar to those observed in previous studies without pretreatment, and pretreatment with antihistamines did not suppress the patient's LFT response.

[0199] It was also observed that CTX320 also induced a reduction in total cholesterol and LDL. No significant differences in other serum chemistry markers induced by CTX320 formulations were found.

[0200] the term In at least some previously described embodiments, one or more elements used in one embodiment may be used interchangeably in another embodiment unless such replacement is technically infeasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the above methods and structures without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter defined by the appended claims.

[0201] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art may convert from the plural to the singular and / or from the singular to the plural where appropriate for the context and / or application. For clarity, various singular / plural arrangements may be expressly set forth herein. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Unless otherwise indicated, any reference to "or" herein is intended to encompass "and / or".

[0202] Those skilled in the art will understand that, in general, the terms used herein, and especially in the appended claims (e.g., the bodies of the appended claims), are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to", the term "having" should be interpreted as "having at least", the term "includes" should be interpreted as "includes but is not limited to", etc.). Those skilled in the art will further understand that if a specific number of an introduced claim statement is intended, such an intent will be explicitly stated in the claim, and in the absence of such a statement, no such intent is present. For example, as an aid to understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim statements. However, the use of such words should not be interpreted as meaning that introduction of a claim statement by the indefinite article "a" or "an" will limit any particular claim containing such introduced claim statement to embodiments containing only one such statement, even when the same claim includes the introductory words "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same applies to the use of definite articles to introduce claim statements. In addition, even if a particular number of introduced claim statements is explicitly stated, one skilled in the art will recognize that such a statement should be interpreted to mean at least the stated number (e.g., merely stating "two statements" without other modifiers means at least two statements or two or more statements). Furthermore, in those cases where a convention similar to “at least one of A, B, and C, etc.” is used, generally such syntactic structure is intended so that one skilled in the art will understand the meaning of the convention (e.g., “a system having at least one of A, B, and C” would include but is not limited to systems having A alone, having B alone, having C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those cases where a convention similar to “at least one of A, B, or C, etc.” is used, generally such syntactic structure is intended so that one skilled in the art will understand the meaning of the convention (e.g., “a system having at least one of A, B, or C” would include but is not limited to systems having A alone, having B alone, having C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.).Those skilled in the art will further understand that, in fact, any disjunctive words and / or phrases presenting two or more alternative terms, whether in the specification, claims or drawings, should be understood to take into account the possibility of including one of the terms, either term or both terms. For example, the phrase "A or B" should be understood to include the possibility of "A" or "B" or "A and B".

[0203] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0204] As will be understood by those skilled in the art, for any and all purposes, such as in providing written description, all scopes disclosed herein also include any and all possible sub-ranges and combinations of sub-ranges of the scope.Any listed scope can be easily identified as fully describing and enabling the same scope to be decomposed into at least equal half, one-third, one-quarter, one-fifth, one-tenth, etc. As non-limiting examples, each scope discussed herein can be easily decomposed into lower third, middle third, and upper third, etc. As will be understood by those skilled in the art, all languages, such as "up to", "at least", "greater than", "less than", etc. include stated numbers, and refer to the scope that can be subsequently decomposed into sub-ranges as discussed above.Finally, as will be understood by those skilled in the art, scope includes each individual member.Therefore, for example, a group with 1-3 articles refers to a group with 1, 2 or 3 articles.Similarly, a group with 1-5 articles refers to a group with 1, 2, 3, 4 or 5 articles, etc.

[0205] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

Claims

1. A method for treating a lipoprotein-related disease in a subject in need thereof, comprising administering to the subject more than one nanoparticle complexed with: (a) a guide RNA (gRNA) targeting the LPA gene (LPA gRNA) or a nucleic acid encoding the LPA gRNA; and (b) a nucleic acid encoding an RNA-guided endonuclease, The subject's lipoprotein-related disease is thereby treated.

2. The method of claim 1, wherein the more than one nanoparticle is administered to the subject two or more times.

3. The method of any one of claims 1-2, wherein each of the two or more administrations is separated by about two weeks to about four weeks.

4. The method according to any one of claims 1-3, wherein each two of the two or more administrations are separated by at least three months.

5. The method of claim 1, wherein the method comprises a single administration of the more than one nanoparticle to the subject.

6. The method of any one of claims 1-5, wherein LPA expression in the subject's plasma is reduced by at least 20%, at least 40%, at least 70%, or at least 90% after the administration.

7. The method of any one of claims 1-5, wherein the concentration of LPA protein in the subject's plasma is reduced by at least 20%, at least 40%, at least 70%, or at least 90% after the administration.

8. The method of any one of claims 5-7, wherein the reduction persists for three weeks, four weeks, five weeks, two months, three months, or more after the administering.

9. The method of any one of claims 5-7, wherein the reduction is 65% one month after the administration.

10. The method of any one of claims 5-9, wherein the reduction is relative to (a) the LPA expression or concentration of LPA protein in the subject's plasma before administration of the more than one nanoparticles; (b) the LPA expression or concentration of LPA protein in one or more untreated subjects; and / or (c) a reference level of LPA expression or concentration of LPA protein in healthy subjects.

11. The method of any one of claims 1-10, wherein the subject in need thereof has an Lp(a) level greater than 50 mg / dl.

12. The method of any one of claims 1-10, wherein the subject in need thereof has an Lp(a) level greater than 100 mg / dL.

13. The method according to any one of claims 1-12, wherein the subject in need thereof has an increased risk of myocardial infarction (MI) unrelated to established cardiovascular disease (CVD) risk factors, or an increased lifetime risk of atherosclerotic cardiovascular disease (ASCVD).

14. The method of any one of claims 1-13, comprising measuring the blood or serum level of Lp(a) in the subject before, during and / or after the administering.

15. The method of any one of claims 1-13, comprising identifying a subject in need of said treatment.

16. The method according to any one of claims 1-15, wherein the lipoprotein-related disease is a metabolic disease, a cardiovascular disease, a lipid metabolism disease, or a combination thereof.

17. The method according to any one of claims 1-15, wherein the lipoprotein-related disease is calcific aortic valve disease, myocardial infarction, coronary heart disease, atherosclerosis, thrombosis, stroke, coronary artery disease, familial hyperlipidemia, myocardial infarction, peripheral artery disease, calcific aortic valve stenosis, or a combination thereof.

18. The method of any one of claims 1-17, wherein one or more symptoms of the lipoprotein-related disease in the subject are reduced or alleviated.

19. The method of any one of claims 1-18, wherein administering the composite of more than one nanoparticles to the subject reduces cardiovascular risk, the likelihood of death related to a cardiovascular event, or a combination thereof.

20. The method of any one of claims 1-19, wherein the nucleic acid encoding the RNA-guided endonuclease is mRNA of the RNA-guided endonuclease.

21. The method of any one of claims 1-20, wherein the RNA-guided endonuclease is a Cas9 endonuclease.

22. The method of claim 21, wherein the Cas9 endonuclease is Streptococcus pyogenes (S. Pyogenes) Cas9, Staphylococcus aureus (S. aureus) Cas9, Neisseria meningitidis (N. meningitides) Cas9, Streptococcus thermophilus (S. thermophilus) Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola (T. denticola) Cas9 or a variant thereof.

23. The method of any one of claims 1-22, wherein the gRNA is a single guide RNA (sgRNA).

24. The method of any one of claims 1-23, wherein the gRNA targets exon 3 of the LPA gene.

25. A method according to any one of claims 1-24, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25.

26. A method according to any one of claims 1-24, wherein the LPA gRNA comprises a spacer sequence of SEQ ID NO:

18.

27. The method of any one of claims 1-24, wherein the LPA gRNA is a single guide RNA (sgRNA) comprising the sequence of SEQ ID NO:

32.

28. The method of any one of claims 1-24, wherein the LPA gRNA is a single guide RNA (sgRNA) comprising the sequence of SEQ ID NO:

11.

29. The method of any one of claims 1-28, wherein the LPA gRNA or the nucleic acid encoding the LPA gRNA and the RNA-guided nuclease are encapsulated in the more than one nanoparticle.

30. The method of claim 29, wherein the nanoparticle is a lipid nanoparticle.

31. The method of any one of claims 1-30, wherein the subject is a primate subject.

32. The method of any one of claims 1-31, wherein the subject is a human.

33. The method of any one of claims 1-32, wherein the method comprises a single administration of the more than one nanoparticle to the subject.

34. The method of claim 33, wherein the more than one nanoparticle is administered to the subject in the single administration at or about 0.1 mg / kg, 0.3 mg / kg, 0.6 mg / kg, or 1 mg / kg of total nucleic acid (a) and (b).

35. The method of any one of claims 1-34, wherein the more than one nanoparticle is a lipid nanoparticle.

36. The method of claim 35, wherein the lipid nanoparticles comprise one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymer-conjugated lipids.

37. The method of claim 35, wherein the lipid nanoparticles comprise cholesterol, polyethylene glycol (PEG) lipids, or both.

38. The method according to any one of claims 1-37, further comprising determining the level of one or more of (i) alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (Alk Phos), and albumin in the subject before, after, or both of the administration; (ii) prothrombin time (PT) and / or (iii) partial thromboplastin time (PTT).

39. The method of any one of claims 1-38, wherein an additional treatment is administered to the subject, wherein the additional treatment comprises administration of a corticosteroid, an anti-H1 antihistamine, an anti-H2 antihistamine, or any combination thereof.

40. The method of claim 39, wherein the additional treatment is administered to the subject 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, or more prior to administering the more than one nanoparticle to the subject.

41. The method of any one of claims 39-40, wherein the additional treatment and the more than one nanoparticle are administered simultaneously.

42. A composition comprising more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an LPA gene (LPA gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25.

43. A composition for use in treating a lipoprotein-related disease, comprising more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an LPA gene (LPA gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 18-25.

44. The composition of claim 43, wherein the lipoprotein-related disease is a metabolic disease, a cardiovascular disease, a lipid metabolism disease, or a combination thereof.

45. The composition of claim 43, wherein the lipoprotein-related disease is calcific aortic valve disease, myocardial infarction, coronary heart disease, atherosclerosis, thrombosis, stroke, coronary artery disease, familial hyperlipidemia, myocardial infarction, peripheral artery disease, calcific aortic valve stenosis, or a combination thereof.

46. ​​A composition according to any one of claims 42-45, wherein the gRNA comprises a spacer sequence of SEQ ID NO:

18.

47. A composition according to any one of claims 42-45, wherein the gRNA comprises the sequence of SEQ ID NO:

32.

48. A composition according to any one of claims 42-45, wherein the gRNA comprises the sequence of SEQ ID NO:

11.

49. The composition of any one of claims 42-48, wherein the Cas9 endonuclease is a Streptococcus pyogenes Cas9 endonuclease.

50. The composition of any one of claims 42-49, wherein the more than one nanoparticle is a lipid nanoparticle.

51. The composition of claim 50, wherein the lipid nanoparticle comprises one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymer-conjugated lipids.

52. The composition of claim 50, wherein the lipid nanoparticles comprise cholesterol, polyethylene glycol (PEG) lipids, or both.

53. The composition of any one of claims 42-52, wherein the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.

Citation Information

Cited By

  • Composition and method for preventing or treating cardiovascular disease

    WO2026194982A1